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ABSTRACT 
  Hepatitis C Virus (HCV) is the primary cause of liver transplantation due 
to its chronic nature in up to eighty percent of infected cases.  Around 3 percent of 
the world’s population is infected with HCV.  Treatment for HCV is a combined 
Ribavirin and interferon-α (IFN-α) therapy effective in only fifty to eighty percent 
of patients depending on HCV genotype.  The growing health concern with this 
disease is the lack of a cure despite liver transplantation.  HCV targets 
hepatocytes, liver cells, but is not cytolytic.  HCV has been shown to induce end 
stage liver disease through sustained inflammation from the host’s immune 
system in the liver.  One of the key dilemmas in HCV research and the search for 
fully effective treatments or vaccines is the lack of animal models.  HCV 
infectivity and disease is limited to primates, most specifically to humans, which 
cannot be fully replicated in any other living being.  The mechanisms for HCV 
evasion or activation of the immune system are complex, many and discoveries 
within this field are crucial to overcoming this destructive hepatic infection.   
Toll-like receptors (TLR) are cellular activators of the innate immune 
system that have been a target of HCV.  Activated TLRs trigger both the 
inflammatory and anti-viral pathways to produce inflammatory cytokines and 
interferons.  HCV proteins have been reported to activate a number of TLRs in a 
variety of cell types.  In order to identify possible targets of HCV within the TLR 
family, we first characterized TLR presence and function in both human hepatic 
carcinoma cell lines and purified primary human hepatocytes.  RNA from TLRs 
1-10 was observed to varying degrees in both the hepatoma cell lines and the 
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primary hepatocytes.  We show the extracellular and/or intracellular presence of 
TLR2, TLR1, TLR3 and TLR7 proteins in hepatoma cell lines.  TLR3 and TLR7 
are located within the endosome and recognize viral RNA products.  We recently 
reported that TLR2-mediated innate immune signaling pathways are activated by 
HCV core and NS3 proteins.  TLR2 activation requires homo- or hetero-
dimerization with either TLR1 or TLR6.  We show NF-κB activation in hepatoma 
cells by TLR2/1, TLR2/6 ligand and HCV protein stimulation.  In primary 
hepatocytes, HCV proteins induced both IL-8 and IL-6 production.  We also show 
that primary hepatocytes initiate a Type 1 IFN response in addition to IL-8 and 
IL-6 production upon stimulation with a TLR7/8 ligand.  Human hepatoma and 
primary hepatocytes are responsive to TLR2, TLR1, TLR6, TLR7/8 ligands and 
HCV proteins.  Activation of these TLRs may contribute to the inflammatory 
mediated destruction caused by HCV or could be targets of HCV contributing to 
its immune evasion.   
We found previously that hepatoma cells and primary hepatocytes are 
responsive to TLR2 ligands and HCV proteins.  We also reported that TLR2 is 
activated by HCV proteins.  Here we aimed to determine whether TLR2 co-
receptors participated in cellular activation by HCV core or NS3 proteins.  By 
designing siRNAs targeted to TLR2, TLR1 and TLR6, we showed that 
knockdown of each of these receptors impairs pro- and anti-inflammatory 
cytokine activation by TLR-specific ligands as well as by HCV core and NS3 
proteins in Human Embryonic Kidney cells (HEK/TLR2) and in primary human 
macrophages.  We found that HCV core and NS3 proteins induced TNF-α and IL-
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10 production in human monocyte-derived macrophages, which was impaired by 
TLR2, TLR1 and TLR6 knockdown.  Contrary to human data, results from TLR2, 
TLR1 or TLR6 knockout mice indicated that the absence of TLR2 and its co-
receptor TLR6, but not TLR1, prevented the HCV core and NS3 protein-induced 
peritoneal macrophage activation.  TLR2 may utilize both TLR1 and TLR6 co-
receptors for HCV core- and NS3-mediated activation of macrophages and innate 
immunity in humans.  These results imply that multiple pattern recognition 
receptors could participate in cellular activation by HCV proteins contributing to 
inflammatory disease.   
Two critical factors in chronic HCV infection are inflammatory disease 
and immune evasion.  We have demonstrated that TLR2 and its co-receptors play 
a role in inflammatory-mediated induction via HCV NS3 and core administration.  
It has recently been shown that HCV targets the TLR3 pathway to aid in immune 
evasion.  TLR3 is only one of four viral recognition receptors located within the 
endosome and it is plausible that HCV may target others.  We hypothesized that 
HCV infection may interfere with the expression and function of TLR7, a sensor 
of single stranded RNA.  Investigating any effect on TLR7 by HCV may reveal a 
new mechanism for HCV immune evasion.  Low levels of both TLR7 mRNA and 
protein were measured in HCV replicating cells compared to control cells while 
reducing HCV infection with either IFNα or restrictive culture conditions restored 
the decreased TLR7 expression.  Downstream of the TLR7 pathway, an increased 
baseline IRF7 nuclear translocation was observed in HCV replicating cells 
compared to controls. Stimulation with a TLR7 ligand, R837, resulted in 
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significant IRF7 nuclear translocation in control cells. In contrast, HCV 
replicating cells showed impaired IRF7 activation.  Use of RNA polymerase 
inhibitors on hepatoma cells, control and HCV replicating, revealed a shorter 
TLR7 half life in HCV replicating cells compared to control cells which was not 
seen in TLR5 mRNA.  These data suggest that reduced TLR7 expression, due to 
RNA instability, directly correlates with HCV replication and results in impaired 
TLR7-induced IRF7-mediated cell activation.   
In conclusion, Hepatitis C Virus manipulates specific Toll-like receptors’ 
expression and their signaling pathways to induce cytokine production.  HCV 
utilizes surface receptors TLR2 and its co-receptors which once activated could 
contribute to inflammatory disease by production of inflammatory cytokines and 
possibly immune evasion. HCV down-regulates TLR7, a viral recognition 
receptor, by decreasing mRNA stability which could facilitate evasion of host 
immune surveillance.   
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CHAPTER I 
INTRODUCTION 
Hepatitis C Virus – The deadly hepatitis virus in America 
Hepatitis C Virus is a growing clinical health concern afflicting close to 
three percent of the world’s population (1), with the largest percentage occurring 
in Egypt, 20% of the nation’s population (2).  Two percent, around five million, 
of the United States’ population (3) is infected with HCV, more than twice as 
high as HIV infections (4).  Unlike other hepatitis viruses, HCV leads to a high 
rate of chronic infection in about eighty percent of the 170 million people infected 
worldwide (1, 5).  It was soon discovered that HCV-induced liver inflammation 
and cirrhosis is one of the leading causes for liver transplantations (6, 7).   
Since the advent of blood transfusion screening (8, 9) and public education 
regarding transmission, the incidence of new infections has dramatically declined 
(10, 11).  Yet, chronic and existing infections may not develop for several years to 
several decades and therefore in America, the incidence of existing infections will 
continue to rise in the near future.  With no vaccine and limited treatment 
efficiencies, HCV will continue to be a world-wide health concern (12).  To 
control for the increasing cases of infection and liver-related complications due to 
infection it is essential to continue to make novel discoveries in HCV research.   
Discovery of a new hepatitis virus 
There are five major characterized hepatitis viruses, hepatitis A-E. (13-
16).  Of the five in America, HCV is the deadliest and most prominent (1, 3, 5, 7).  
Unlike HCV, effective vaccines are available for HAV and HBV (17, 18).  In the 
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mid 1970s a new hepatitis virus was recognized in blood transfusion recipients, 
identified as non-A, non-B hepatitis (19).  A few distinctive characteristics aided 
in separating this new virus from HAV and HBV.  Infection in chimpanzees 
produced chronic disease portrayed by inflammation and hepatocyte structural 
changes (20, 21).  Complete identification of the new virus was hindered by 
difficulties in producing a cellular model permissive to the viral replication (22).  
In 1987, Michael Houghton and Daniel Bradley collaborated to create a molecular 
cloning technique to sequence the viral genome (23).  Once HCV was identified, 
screening for it in blood transfusions became mandatory starting in 1990 which 
subsequently decreased the rate of infection (24).  Transmission of the virus in 
some areas is still growing despite the advanced techniques to identify HCV in 
blood (25).  The highest transmission rates were initially from unsanitary injection 
drug use or unsterile needle use as in unregulated body tattoo art and blood 
transfusions (26).  Since the screening of blood there has been a decrease in 
developed countries but due to the expensive nature of testing for HCV, 
underdeveloped countries are still struggling to control the spread of the virus 
(27).  Occupational exposure to HCV is and has been the most difficult type of 
transmission to control as most infections occur accidentally even with proper 
precautions observed (28).  Continued HCV research has consequently led to 
treatment against the virus. 
HCV infection and treatment: acute vs chronic  
HCV infection results in two forms, either an acute infection followed by 
clearance or acute infection followed by persistence (29, 30).  Diagnosis of the 
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acute phase followed by clearance is rarely made as the symptoms are so slight 
that most HCV acutely infected patients do not require medical assistance (31, 
32).  In almost all infected individuals antibodies against HCV can be detected 
within 3 to 6 months after initial infection, while symptoms from chronic 
infection may not materialize for decades after the initial infection (33).  PCR is 
used to confirm infection in all patients and it is critical for those that have low 
antibody titers (34).  Around twenty to fifty percent of HCV infected patients are 
spontaneously cured while the chronic disease is seen in eighty to fifty percent of 
infected individuals (1, 33, and 35).  Roughly half of the chronically infected 
individuals can eliminate HCV after a pegylated IFN-α and ribavirin combined 
therapy for up to 48 weeks depending on HCV genotype, while non-responders 
develop potentially fatal chronic disease (5, 35, 36, and 37).  A major 
characteristic and possibly a vital participant in persistent HCV infection is 
chronic inflammation in and outside the liver mediated by cytokines such as 
tumor necrosis factor-alpha (TNF-α) (38), interleukin 12 (IL-12) (39), and 
interleukin 6 (IL-6) (40, 41).  Chronic infection can cause liver cirrhosis and/or 
hepatocellular carcinoma, ultimately leading to liver failure due to inflammatory 
cell-mediated liver damage (42).  Chronic liver inflammation from HCV infection 
is thought to be either inactivated or maintained by immune-mediated 
mechanisms. 
HCV histology 
 In HCV infected individuals, chronic infection can lead to elevated alanine 
aminotransferase (ALT) levels.  Even though testing for ALT is the most 
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inexpensive measure for liver injury, it is not the most accurate and in chronic 
infection may not be elevated at the time of testing (43, 44).  The most accurate 
procedure to investigate histological changes in chronic HCV is from a liver 
biopsy of HCV chronically infected individuals.  Liver histology shows persistent 
mononuclear cell invasion into the parenchyma and portal vein areas, hepatocyte 
necrosis and differing grades of fibrosis.  Fibrosis is an accumulation of 
extracellular matrix proteins such as collagen.  Fibrosis can eventually lead to 
cirrhosis of the liver, a condition where the liver tissue is replaced with fibrotic 
scar tissue inhibiting liver function, and/or liver failure (45).  Recent analysis of 
liver histology of chronic HCV patients showed that fibrosis as opposed to 
steatosis, accumulation of lipids within the cell, was associated with HCV 
infection (46).    
The distribution of viral HCV RNA is mainly in the liver, with the 
majority of RNA within the hepatocytes (47).  Viral RNA and HCV core antigen 
have also been isolated from the serum (47) and HCV core protein was found in 
the cytoplasm of hepatocytes (48).   
HCV virology 
HCV is a single-stranded positive sense RNA virus from the Flaviviridae 
family (14, 49).  The genome is approximately 9.6 kilo-bases and has six different 
major genotypes, genotypes 1-6 (14, 36).  HCV has a high propensity for genetic 
variations due to the error prone nature of the RNA replicase (50, 51).  Therefore, 
HCV infected individuals with certain genotypes and subtypes respond atypically 
to treatment and the identity of HCV genotypes in infected individuals is 
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important to the specific treatment regimen for the individual.  Throughout the 
history of HCV therapy, treatment has been conventionally less effective, up to 
30-50%, in patients harboring HCV genotype 1 compared to up to 80% effective 
clearance in genotypes 2 and 3 (32, 36, and 52).  Thus, genotype 1 is associated 
with the development of chronic infection and is also the most prevalent genotype 
in America (36).   
1. HCV proteins 
HCV is a relatively small 50 nm enveloped RNA virus (53, 54).  The 
genome flanked by small 5’ and 3’ non-translated regions (NTRs) have one open 
reading frame that translates to a number of proteins of roughly 3000 residues (29, 
55, and 56).  The 5’NTR region contains an internal ribosomal entry site (IRES) 
and is highly conserved among the various genotypes and subtypes.  It is essential 
for RNA translation by binding the 40S ribosome subunit positioning it near the 
initiation site (57-59).  The 3’NTR region with its three domains, variable region, 
polyU region, and a conserved terminal domain, is highly inconsistent among the 
genotypes (60, 61).  Areas in the latter two regions are required for RNA 
replication (61-63).  The virus has ten proteins with three structural proteins: core, 
envelope 1 and 2 (64-66).  In between the structural and nonstructural proteins 
there is a small integral membrane protein: p7 (67).  The non-structural proteins 
are: NS2 (68, 69), NS3, NS4A, NS4B, NS5A, and NS5B.  NS3 through NS5B are 
required for replication (68, 69).    Extensive research into each of these proteins 
has revealed specific roles for viral replication and survival.   
1a: Structural proteins 
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The three structural proteins make up the HCV viral particle which 
consists of the nucleocapsid or core protein covered by two envelope 
glycoproteins, E1 and E2 (70).  The viral particle, shown in Figure 1.1, constitutes 
these three proteins and possibly the p7 protein which has yet to be confirmed in 
the virion.  The envelope proteins, E1 and E2, are glycosylated and are secured to 
the lipid membrane by their C-terminal transmembrane domain (71).  E1 and E2 
form the HCV glycoprotein complex that binds to cellular receptors required for 
attachment and fusion into the cell (72-74).  E1 has been shown to aid in E2 
protein folding (75).  E1 and E2 can either form heterodimers with noncovalent 
bonds or misfolded aggregates held together by disulfide bonds (76-78).   
HCV core protein is a highly basic RNA binding protein that can also 
stimulate the innate immune inflammatory pathways via TLR2 and plays an 
important role in the formation of viral nucleocapsids and interactions with the 
viral genome (65, 79, and 80).  The core protein is located intracellularly in 
infected hepatocytes; however, there are relatively high levels of core protein 
detected in patients’ blood (81).  During infection, HCV core protein is circulating 
in the blood stream and can stimulate cell surface receptors throughout the host.  
The core protein consisting of the first 191 amino acids in the polyprotein is a 
relatively small protein, ~21kDa, also contains DNA binding motifs, nuclear 
localization signals and phosphorylation sites (82-85).  The protein localizes in 
the cytoplasm but can also localize in the nucleus (86, 87).   
The structural proteins compose the viral particle shown in Figure 1.1.  
The structural proteins, E1, E2 and core are associated with the endoplasmic 
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reticulum and cleaved from the HCV polyprotein complex and endoplasmic 
reticulum membrane by host and viral enzymatic reactions at multiple signal 
peptidase cleavage sites shown in Figure 1.2 (69, 88).  
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Figure 1.1: Schematic diagram of HCV virus particle.  Envelope glycoproteins E1 
and E2 are cellular attachment receptors.  The core protein, nucleocapsid, 
encompasses the single stranded RNA.   
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1b: ion channel protein 
The p7 protein is a very small polypeptide, 7kDa, located between the 
structural and non-structural HCV proteins (Figure 1.2, 67).  It has two 
transmembrane domains positioned so both amino and carboxy termini face the 
endoplasmic reticulum lumen with peptidase cleavage sites at both ends (89).  
The protein is observed to have ion channel function in artificial lipid membranes 
and is necessary for HCV infection in chimpanzees (67, 90).  Recent evidence on 
p7 has supported its vital role in infectious viral production (91), assembly and 
release of the virus (92, 93). 
1c: non-structural proteins 
The non-structural proteins are not associated with the viral particle but 
are essential for viral replication and immune evasion.  NS2 is not required for 
HCV replication and very little is known about its specific function (94).  
Expressed alone, NS2 localizes to the ER membrane.  Dimerization of NS2 yields 
a cysteine protease with two active sites which cleaves between NS2 and NS3 
(95).  Due to this function, researchers believe it is involved in viral assembly and 
release.  NS2 can also bind host pro-apoptotic protein, CIDE-B, which 
subsequently inhibits apoptosis (96).  NS2 is marked by the host cell for 
proteasome degradation soon after it is translated (97).   
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Figure 1.2: HCV protein association with host endoplasmic reticulum.  Structural 
proteins, core, E1, and E2, have signal peptidase sites targeted for ER peptidase 
cleavage indicated by grey pacmen between core and NS2.  Non-structural proteins 
located either within the membrane or on the cytoplasmic side of the ER have a 
cysteine protease cleavage site from NS2 to NS3 indicated by the light grey pacman 
and viral serine protease sites from NS3 to NS5B that are cleaved by viral proteases 
indicated by white pacmen. 
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HCV NS3-NS5B proteins have been shown to be required for replication 
and thus one of the initial HCV cell culture models, Blazing Blight 7 or BB7, 
contains only these proteins (98).  NS3 has a variety of functions.  At its amino 
terminal it contains a serine protease domain yet at its carboxyl terminus there is 
an RNA helicase/NTPase domain (99, 100).  NS3 on its own functions 
inadequately, diffusing to the cytoplasm and nucleus, and is marked for 
proteolytic degradation.  Upon formation of the NS3-NS4A complex, NS3 
localizes to the ER membrane and both the protease and helicase activity are 
greatly enhanced (101, 102).  Monomeric NS3 binds RNA but homodimerization 
is required for unwinding (103).  The serine protease domain in conjunction with 
NS4A cleaves processing sites located between the rest of the non-structural 
proteins (101, 102).   These functions are required for HCV to form the 
replication complex (104).  NS4A is a membrane protein that covalently binds to 
NS3 and this complex, NS3/4A cuts processing sites.  NS4A also targets NS3 to 
the cytoplasmic side of the ER membrane and protects NS3 from degradation 
(101, 102).  NS3/4A is also very important for HCV immune evasion and 
manipulation of host cellular factors (105-107).  NS4B is a transmembrane 
protein that is thought to contribute to the formation of HCV membranous 
replication complexes by altering intracellular membranes.  Mutations in this 
protein affect replication efficiency (108, 109).  Like p7, the exact function is 
unknown leaving further research to be desired.   
NS5A is a phosphoprotein associated with the ER membrane (110, 111).  
It exists in either a hypo- or hyper-phosphorylated state which regulates RNA 
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replication (112-114).  Hypo-phosphorylation is required for efficient HCV 
replication in cell culture and therefore modifications such as point mutation, 
(S2240I), to NS5A are necessary for permissibility (98, 115).  NS5A can also 
bind a number of viral and host proteins to promote RNA replication and immune 
evasion (116-118).  NS5B is the RNA-dependent RNA polymerase absolutely 
required for HCV replication (119, 120).  It is secured to the ER membrane by a 
carboxy terminal domain and interacts closely with NS5A and NS3 (90, 121).  
The protein has a distinct polymerase feature of a fully encircled active site which 
serves to regulate RNA synthesis (122).  NS5B has also been implicated in 
manipulating host survival and defense mechanisms by binding to specific host 
proteins (123-125).   
2. Viral life cycle 
HCV invades and replicates in human hepatocytes.  Chimpanzees are the 
only other animal model that will sustain replication (126).  The HCV life cycle 
consists of five distinct steps: entry, protein translation, RNA replication, virion 
assembly, virion release.  The viral infection starts by binding of the envelope 
proteins to several host cellular receptors: CD81 (127); scavenger receptor class 
B-1 (SRB1) (128); glycosoaminoglycans (129); low density lipoprotein receptor 
(LDLR) (129, 130); claudin-1 (131).  Endocytosis of the virion occurs by clathrin 
mediation and acidification of the endosomal compartment.  After entry the viral 
and endosomal membrane fuse allowing for the release of HCV RNA into the 
cytoplasm (132-134).  The positive single stranded HCV RNA is dependent on 
the 5’NTR IRES to begin translation of the polyprotein (64, 65, 133).  The 
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proteins, core, E1, E2, p7, NS2, NS3, NS4A, NS4B, NS5A, NS5B, are 
manufactured in the cytoplasm and localize to the endoplasmic reticulum 
membrane where HCV negative sense strand RNA production occurs (90, 102, 
109, 111, 116, 135-139).  In the cytoplasm while HCV proteins are translated 
from RNA, the proteins may interact with host factors to ensure viral survival.  
HCV proteins in particular NS4B, mediate the formation of membranous webs 
postulated to be partial ER membranes, where further RNA replication from 
negative strand to positive strand occurs (109).  Close to the membranous webs, 
the RNA and structural proteins assemble into viral particles which bud into the 
ER or similar membrane compartments to exocytose out of the cell leaving it 
intact (77, 136, 140).   
HCV cell culture: advances and setbacks 
Despite the great increase in HCV research since its identification in 1989, 
there are still a number of areas that are unknown.  The primary host for HCV is 
the human hepatocyte (141).  HCV tropism is not limited to hepatocytes, but has 
been found in peripheral blood mononuclear cells and the brain, yet HCV 
replication in these tissues has not been confirmed (142, 143).  Others have 
reported HCV in the bone marrow, serum, spleen, thyroid, pancreas, lymph nodes 
and adrenal glands, but some groups have shown in bone marrow and sera that 
due to the nature of the PCR testing the presence of HCV was most likely an 
artifact or experimental error (144-147).  Since HCV positive patients with liver 
transplants have a 100% re-infection rate, HCV must at least seek refuge in other 
non-hepatic tissues (148).  The largest challenge for researchers is the lack of an 
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animal model.  The chimpanzee is the only other species that can permit HCV 
infection with similar pathogenesis as the human (149).  Even though the 
chimpanzee has been used in HCV research, it is not common mainly due to the 
expense and time required to utilize the animal model for infection (150).   
The chronic infection exhibited by HCV infected patients, pressured 
scientists to develop a cell culture system permissive for HCV replication.  More 
than ten years after the discovery of the HCV genome, the first efficient HCV cell 
culture system was reported by Dr. Charlie Rice (98, 115).  This cell culture 
system required mutations in the HCV NS5A protein and adaptive mutations in 
the hepatoma cell line, Huh7 (98, 115).  Two distinctive cell culture lines were 
produced: BB7, an HCV subgenomic (NS3-NS5B) line and the full length (FL) 
which contains the sequence of all HCV proteins (98, 115).  We utilized both cell 
lines for further investigations with HCV and the innate immune system presented 
in this thesis.  Once these cell cultures were reported and openly shared by Dr. 
Rice, tremendous advances in HCV research were possible.  Even though the 
HCV field could now move forward, it was still held back by the lack of a 
complete cell culture system (115).  All cell culture systems created up to that 
point only allowed for viral replication within the cell but did not allow for active 
viral particle assembly, leaving half the viral life cycle unaccounted for and also a 
lack of an infectious HCV cell culture model.  A few years later in 2003, 
scientists in Japan discovered the first and to date the only infectious HCV clone 
able to replicate in hepatoma cell culture (151).  Dr. Takaji Wakita isolated an 
HCV genotype 2a species, JFH-1, from a patient with fulminant hepatitis.  JFH-1 
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replicates, assembles, releases and infects hepatoma cells, Huh7 and Huh7.5, a 
variant of Huh7 with further adaptive mutations to create a more permissive 
infectious environment.  With the newly discovered infectious clone, the full 
HCV life cycle is being explored, but the lack of an appropriate animal model is 
still inhibiting further discoveries for effective vaccines and treatment for non-
responders.   
Immune reaction to HCV infection 
Despite the lack of an appropriate animal model and before the 
development of the cell culture system, scientists and medical researchers have 
been investigating the effects of HCV on the host immune system in HCV 
infected patients and chimpanzees.   Researchers have found both an innate and 
adaptive immune reaction against HCV which the virus has developed ways to 
circumvent (9, 29, 41, 152, and 153).  Initial infection causes activation of the 
innate immune system before the adaptive system can either clear infection or 
allow chronic infection to set in.    
1. Adaptive immunity against HCV 
The adaptive immune response plays a very important role in acute 
infection and clearance.  Seroconversion can take up to three months after initial 
infection is established (154, 155).  With acute HCV infection that leads to 
clearance of the infection, antibodies in the serum diminish to undetectable levels 
(156).  One mechanism of clearance in acute infections can be attributed to HCV 
specific antibody neutralization.  This was demonstrated in chimpanzees with 
anti-E2 against the hypervariable region (157).  Chronic infection can cause 
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increasing levels of antibodies to develop throughout the infection (33).  Those 
who do not develop a T-cell response or a weak response are more likely to 
develop chronic infection (159).  The mechanisms for non-functional T-cell 
response are not well known, yet recently high expression of programmed death-
1, PD-1, on CD8+ T-cells was demonstrated in HCV infected patient livers.  This 
inhibitory co-stimulatory receptor inhibits T-cell function when highly expressed 
and it was shown that PD-1 expression reduced upon low viral titers or clearance 
of HCV infection (160).  Blockade of PD-1 could not fully restore T-cell function 
in HCV infected patients which proves the complex nature HCV infection can 
have on adaptive immunity.  A major defense mechanism against HCV specific 
B- and T-cell responses is the generation of escape mutations by the virus that are 
potentially caused by a variety of  B-, T-cell epitopes (161-163).  T-cell responses 
are directed towards these mutations which are ineffective in aiding with 
clearance.   
2. Innate immunity against HCV 
We have chosen to focus this research on the innate immune response to 
HCV infection in HCV replicating cell lines.  HCV targets the innate immune 
response by a number of mechanisms which if discovered can help aid in 
innovative treatments for chronically infected patients.  In addition to hepatocytes, 
the liver contains a number of different cell types such as stellate cells that store 
vitamin A (164), Kupffer cells that serve as resident liver macrophages (165), 
circulating natural killer cells (NK) that are involved in innate immune 
surveillance (166), circulating T-cells and dendritic cells (DC).  Hepatocytes and 
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other innate immune cells within the liver, such as Kupffer cells (167, 168), have 
many viral defense mechanisms to clear the infection, including the production of 
inflammatory cytokines and Type 1 interferons, which are involved in the clinical 
treatment of HCV (38, 79).  Inflammatory cytokines and IFNs are produced 
within the cell by triggering viral recognition receptors which include the 
following receptors: cytoplasmic localized receptors, protein kinase R (PKR), 
RNA helicase receptors (RIG-I and MDA-5), NOD-like receptors, 2’5’ 
oligoadenylate synthetase (OAS) as well as the following membrane bound 
receptors: TLRs and mannose receptors.   
3. Cytoplasmic innate immune receptor response to HCV 
PKR binds double stranded RNA and activates apoptosis, preventing 
further spread of the virus.  PKR, the double stranded RNA dependent protein 
kinase induced by IFNs (169), was one of the first receptors identified to be 
inhibited by the HCV proteins E2 (170, 171) and NS5A (172, 173).  2’5’OAS is 
activated by dsRNA, mostly viral (174).  Once activated it produces 2’5’ 
adenylate that binds RNaseL and induces RNaseL dimerization.  Activated 
RNaseL cleaves single stranded regions of RNA, with a preference towards viral 
RNA (175).  2’5’OAS is enhanced by Type 1 IFNs but it is still controversial 
whether HCV NS5A inhibits or HCV core protein stimulates 2’5’OAS (176, 177).  
Most recently, HCV NS3/4A protease was shown to inhibit the RNA helicase 
family (178).  RIG-I and MDA-5 are cytoplasmic receptors that sense single and 
double stranded RNA triggering a cascade of events including phosphorylation, 
dimerization and nuclear translocation of IRFs which leads to activation of Type 1 
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IFNs (179-181).  Since HCV RNA is found in the cytoplasm, RIG-I and MDA-5, 
cytoplasmic viral recognition receptors, are extremely important in inducing an 
initial antiviral response to inhibit further replication and infection.  RIG-I and 
MDA-5 share a very similar IFN induction pathway with TLR3, where all three 
receptors induce IFNβ production via IRF3/IRF7 activation.  With overlapping 
pathways for IFN induction, these receptors can survey for viral activity in the 
cytoplasm and in endosomes.  HCV NS3/4A cleaves the adaptor protein, IPS-
1/MAVS/VISA/Cardif, to MDA-5 and RIG-I at the transmembrane region 
associated with the mitochondrial membrane which is necessary for receptor 
activation (178).  By inhibiting RIG-I and MDA-5, HCV replication is not 
hindered by their ability to activate IFN induction.   
4. Toll-like receptors 
One of the larger families of innate immune surveillance proteins is the 
Toll-like receptors, TLRs (182).  Toll was first discovered to participate in 
dorsoventral patterning during embryogenesis in Drosophila melanogaster, 
household fruit fly (183).  These receptors were then seen to play a role in 
Drosophila immunity (184).  It was soon discovered that there were analogous 
receptors in mammals, 13 discovered to date, 10 of which exist in humans (182, 
185).  TLRs are cell surface or endosomal transmembrane receptors that initiate 
signaling pathways that produce pro- and anti-inflammatory cytokines when 
stimulated by pathogen-derived ligands (182, 186-188).  These receptors have 
extracellular leucine rich repeat domain and an intracellular TIR (Toll/Interleukin-
1 receptor) domain (187).  The extracellular domain recognizes pathogen 
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associated molecular patterns while the intracellular domain binds adaptor 
proteins, such as myeloid differentiation factor 88 (MyD88/Mal) (189) and/or 
TIR-domain containing adaptor inducing IFNβ (TRIF).  Activation of TLRs 
initiates a cascade of events leading to NF-κB, nuclear factor kappa B, or IRF, 
interferon regulatory factor, nuclear translocation (190).  NF-κB is a transcription 
factor that binds to promoter regions of a considerable number of genes, 
producing pro- or anti-inflammatory cytokines and chemokines (191, 192).   
Another activation pathway utilizes IRFs that are transcription factors that bind 
specifically to promoter regions of IFNs (193). 
Ascertaining TLR expression and function in hepatocytes that respond to 
HCV proteins 
Hepatocytes were thought to contribute very little to innate immune 
surveillance, yet recently hepatocytes were shown to express a number of TLRs, 
expanding their function during viral infection (194, 195).  We set out to examine 
the expression and function of TLRs in hepatocytes.  We concentrated on two 
TLRs, TLR2 heterodimers and TLR7.  HCV proteins activate TLR2 (79) while 
TLR7 agonists were seen to reduce HCV infection (196, 197).  Both TLRs are 
highly expressed in innate immune cells including macrophages (198) and 
dendritic cells, (199) yet it was unknown whether TLRs are expressed and 
functional in hepatocytes.  Therefore we examined the extent of expression and 
function by looking at RNA, protein and cytokine production.  We determined 
that hepatocytes substantially express TLR2, TLR1, and TLR7.  These TLRs 
activate either the NF-κB pathway and/or the IRF pathway upon specific ligand 
20 
 
stimulation.  We also saw a large induction of inflammatory cytokines in 
hepatocytes when we stimulated with HCV proteins core and NS3 but not NS5A. 
TLR2 signaling pathway 
Activation of TLRs results in homo-dimerization (TLR4, 200) or hetero-
dimerization (TLR2/1 or TLR2/6; 201).   TLR2 can recognize a diverse number 
of ligands from gram+ and gram- bacterial products such as peptidoglycan (PGN), 
or mycobacterial lipoproteins, to zymosan from yeast (202).  Formation of TLR2 
heterodimers activates MyD88 which recruits a number of other kinases, mitogen 
activated protein kinase 37 (TAK1), and inhibitor of kappa B kinases (IKK).  
IKKs phosphorylate the inhibitor of kappa B (IκBα) which prevents the NF-κB 
complex from translocating into the nucleus (203).  Phophorylated IκBα is 
marked for proteosomal degradation while the released NF-κB complex is free to 
move into the nucleus activating a number of genes.  Current research revealed 
that HCV core and NS3 proteins could stimulate the innate immune system in 
monocytes and macrophages by activating the TLR2-mediated inflammatory 
cytokine pathway (79).   
Investigating the identity of TLR2 heterodimer contributing to HCV protein 
recognition  
Some TLRs, such as TLR2, 4, 3, 7, and 9, are involved in detection of 
viral proteins (106, 179, 204, and 205).  Kupffer cells in the liver have the ability 
to produce a significant amount of cytokines when stimulated (206).  Kupffer 
cells may contribute to inflammatory cell recruitment to the liver and be 
responsible for further liver damage such as fibrosis or cirrhosis (167).  In a 
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previous study, TLR2-specific activation by HCV NS3 and core proteins but not 
HCV E2 protein was shown in monocytes and macrophages (79).  HCV core and 
NS3 proteins interact with many host proteins (79, 207); however, all the 
mechanisms by which HCV proteins modulate the innate immune system that 
contribute to disease are not fully answered.  Existing research illustrates that 
TLR2 homo- or hetero-dimerizes with TLR1 or TLR6 (186, 201).  Therefore, to 
further identify the receptor recognition of TLR2-specific HCV protein activation, 
we created a knockdown system using RNAi in TLR-expressing human cells, 
human embryonic kidney cells (HEK/TLR2), and primary macrophages, human 
monocyte derived macrophages (hMDMs).  We also utilized TLR-specific 
knockout mice to confirm our results.  Our results revealed that in HCV protein 
stimulated HEK/TLR2 or hMDM cells, TLR1 or TLR6 siRNA knockdown 
caused a significant loss of cytokine production.  These results suggest that in 
both HEK/TLR2 and hMDM cells HCV protein activation of TLR2 utilizes either 
TLR1 or TLR6.  We show that HCV core and NS3 proteins stimulate the host’s 
innate immune system (TLRs) to produce inflammatory cytokines.   Identifying 
receptors activated by HCV proteins is important in discovering novel therapeutic 
targets to reduce inflammation in the liver (79, 208).  
HCV immune escape via interference with IFN-mediated pathways 
Some HCV-derived products, including HCV RNA and several HCV 
proteins trigger host defense (79, 173). Immune responses, including cell-
mediated immunity and Type 1 IFNs are vital in controlling and clearing HCV 
infection (209, 210). A number of host receptors, including TLR3, TLR7, TLR8, 
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TLR9, RIG-I and MDA-5 lead to a Type 1 IFN-mediated response upon 
stimulation with viral RNA (179, 181, 211, and 212).  However the virus has 
developed mechanisms to bypass the immune defense and facilitate viral 
persistence.  HCV proteins not only stimulate TLRs but can inhibit TLR-mediated 
pathways by disrupting TLR3-mediated type 1 interferon induction (106).  HCV 
NS3/4A cleaves TRIF, the adaptor protein for the IFN-induction pathway of 
TLR3.  Viral recognition receptors can compensate for the loss of one another 
although during HCV infection, disruption of TLR3, MDA-5, and RIG-I 
pathways greatly diminishes IFNβ production and allows for continued viral 
replication and infection.  Immune escape from HCV proteins may manifest not 
only in the disruption of TLR3 or RIG-I/MDA-5-mediated signaling machinery 
but also affect other IFN-inducing pathways such as activation of IRF7 which 
contributes to IFNα production (178).   
IFN and its detrimental effects against HCV 
 Over fifty years ago, a new family of cytokines, IFNs, was discovered to 
interfere with influenza virus replication (213, 214).  IFNs are an important 
component involved in innate immune activation against viruses and have been 
manufactured as effective therapy against a number of viral infections.  There are 
three subfamilies of IFNs, type 1, type 2, and type 3.  Type 1 IFNs include: 13 
IFNα subtypes, IFNβ, IFNκ, IFNε, IFNο, IFNτ and IFNδ, that all bind the IFNα 
receptors 1 and 2.  Type 2 is IFNγ signaling through the IFNγ receptor.  Type 3 
consists of the IFNλ1, 2 and 3 genes and signal through the IL-10 receptor 2 and 
the IFNλ receptor 1 (215).  All IFNs stimulate the JAK/STAT pathway to activate 
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a number of anti-viral or anti-microbial interferon stimulated genes (ISGs) (216).  
ISGs activate a number of immune cells such as macrophages (217), NK cells 
(218), T-cells (219) which up-regulate major histocompatibility class 1 and 2 
(220).  They also induce activation of anti-viral and anti-microbial enzymes such 
as PKR and 2’5’OAS/RNaseL which cleaves viral RNA (221, 222).  TLRs are 
one of many types of receptors that stimulate the production of IFNs. 
Like IRF3, mediated by TLR3 activation, IRF7 is a transcription factor 
responsible for Type 1 IFN production (223).  It is mainly activated by viral 
recognition receptors, TLR7, TLR8, or TLR9, through a series of phosphorylation 
events starting with MyD88, the main adaptor protein for most TLRs (223, 224).  
Once the receptor is stimulated, a complex is formed between MyD88, TRAF6, 
IRAK4, and IRAK1 that allows activation of IRF7 (225).  Both TRAF6 and 
IRAK1 have been reported to be responsible for phosphorylating IRF7 leading to 
its homodimerization and subsequent nuclear translocation.  Unlike TLR3, TLR7 
pathway mainly utilizes IRF7 for activation of Type 1 IFNs, mainly IFNα.   
TLR7: another target for HCV immune evasion 
Recent reports indicated that robust TLR7 agonists decreased HCV RNA 
in HCV infected patients (196) and HCV RNA and NS5A protein in HCV 
replicating hepatoma cells (197).  TLR7 has also been reported to recognize other 
single stranded RNA viruses such as influenza (226, 227) and dengue (228).  
TLR7 also recognizes polyU sequences in viral RNA which are found in the HCV 
3’NTR (229, 230).  Based on these reports, we postulated that TLR7 may play a 
role in HCV infection and analyzed the hypothesis that HCV, in an effort to 
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bypass immune surveillance, interferes with TLR7 expression and function. Our 
results demonstrate that HCV infection causes instability of TLR7 RNA, thus 
leading to low TLR7 RNA and protein expression and impaired TLR7-mediated 
activation of the IRF7 signaling pathway. 
General Thesis Objectives 
The general objective for this thesis was to determine the effects of HCV 
infection on Toll-like receptors.  I concentrated my research on investigating these 
effects in two cell types: hepatocytes, the main cell type in the liver and host to 
HCV replication; human monocyte derived macrophages, similar to Kupffer cells 
(liver macrophages) that participate in inflammatory cytokine production upon 
viral infection.  It is very important to understand the mechanisms behind HCV 
induced cellular activation and HCV immune escape as further research will pave 
the way for effective treatment in those chronically infected patients who are not 
responsive to current treatment.   
We pursued the discovery of TLR expression in hepatocytes to see 
whether these cells might participate or be a target of HCV cell activation.  We 
also wanted to learn whether hepatocytes could be activated by HCV proteins to 
produce inflammatory cytokines.  These results might suggest another role for 
hepatocytes in inflammatory liver disease.  Previously it was shown that HCV 
proteins, core and NS3, stimulated human monocytes (innate immune cells 
actively participating in inflammatory cytokine production) through TLR2.  TLR2 
heterodimerizes with TLR1 or TLR6 and we aimed to further identify which 
receptor complex is required for HCV protein mediated TLR activation in human 
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macrophages.  Findings for these objectives will help distinguish which co-
receptor could be involved in the activation by HCV proteins and show that HCV 
NS3 and core could be broadly recognized by multiple cellular receptors.  Others 
have shown in hepatocytes that HCV NS3/4A protease activation inhibits the 
TLR3 and RIG-I/MDA-5 IFN-mediated pathway.  There are a number of 
receptors that can trigger IFN production in hepatocytes and HCV has developed 
ways to inhibit a majority of them.   Single stranded RNA viruses trigger TLR7 to 
produce IFNα.  Alterations of TLR7 in HCV infected hepatocytes have not been 
investigated and we aimed to explore the effects on TLR7 and mechanisms by 
which the effects may occur.  We intended to determine the expression of TLR7 
in HCV replicating cells and any mechanisms for effects on TLR7.  We aim to 
demonstrate the possibility for another target of HCV and a novel mechanism by 
the virus to continue infection.    
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CHAPTER II 
MATERIALS AND METHODS 
PART 1: Characterization of TLRs in hepatocytes. 
Reagents:  
Dulbecco’s Modified Eagle Medium, (D-MEM) and RPMI 1640 were 
from Gibco (Grand Island, NY), fetal calf serum (FCS) was from HyClone 
(Logan, UT).  Blasticidin was from Invivogen (San Diego, CA).  Phenol-purified 
lipopolysaccharide (pLPS) was from List Biological Laboratories (Campbell, 
CA); PAM2CSK4 (Pm2) and PAM3CSK4 (Pm3) from EMC Microcollections 
GmbH (Germany); R848 was from 3M Pharmaceuticals (St. Paul, MN); TNF-α 
was from BD Biosciences (San Jose, CA).  Recombinant HCV core, NS3, and 
NS5a proteins were purchased from Biodesign (Saco, ME).  HCV NS3 and core 
proteins were fused with E coli derived β-galactosidase at the N-terminus and had 
>95% purity as evaluated by SDS-PAGE.  Further purification of recombinant 
proteins was performed by S-Sepharose-Ceramic Hydroxyapatite-Affinity 
purification by Biodesign.  β-galactosidase, was expressed and purified identically 
to HCV core and NS3 proteins (kindly provided by Biodesign), and was used as a 
control where indicated.  To confirm there were no immunogenic affects from β-
galactosidase we stimulated cells with β-gal alone.  Lipopolysaccharide 
contamination of recombinant proteins (at a concentration of 10 μg/ml) was lower 
than 0.01 EU/mL, as determined by Limulus amebocyte assay (Kit QCL-1000; 
BioWittaker Inc., Walkersville, MD).  The minimum limit of detection by the 
LAL assay is 12 picograms of endotoxin. 
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Cells:  
All cells were grown in 5% CO2 at 37°C and passed at 75% confluency.  
Human (Homo sapiens) hepatoma cell lines, Huh7 and Huh7.5 were maintained 
in DMEM with 10% heat inactivated FCS, 1% non-essential amino acids and 500 
μg/ml Ciprofloxacin.  Human hepatocytes were obtained from Cambrex (North 
Brunswick, NJ) adhered to 24 well plates coated with matrigel.  Human 
hepatocytes were 97% pure and purified by high speed centrifugation and several 
other purification techniques undisclosed by Cambrex.  After purification, a 
sample of hepatocytes was tested for enzymatic activity and functions for albumin 
production, phase 2 activities, and cytochrome p450 activity.  Hepatocytes tested 
negative for Hepatitis C virus, Hepatitis B virus, human immunodeficiency virus, 
human T-cell lymphotrophic virus 1 and 2, and Syphilis by RPR (rapid plasma 
reagin).  Hepatocytes with abnormal, low or high functional or enzymatic 
activities were not released by Cambrex.  They were maintained in hepatocyte 
media consisting of hepatocyte basal medium with ultraglutamin-1 (Cambrex) 
with a 1:50 dilution of bovine serum albumin, rhEGF (epidermal growth factor), 
insulin, ascorbic acid, gentamicin sulfate amphotericin B, transferrin, and 
hydrocortisone 21 hemisuccinate.   
Peripheral blood mononuclear cells (PBMCs) were isolated from HCV 
negative, healthy human blood donors using Ficoll-Paque density gradient 
centrifugation. 
Human monocyte-derived macrophages were differentiated from 
monocytes isolated from peripheral blood mononuclear cells of HCV negative, 
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healthy human blood donors using Ficoll-Paque density gradient centrifugation.  
Monocytes were separated from PBMCs by adherence to flasks coated for two 
hours with 2% sterile, endotoxin-free gelatin and dried overnight in a 37°C, 5% 
CO2 incubator.  Before addition of peripheral blood mononuclear cells, the flasks 
were additionally coated for one hour with platelet-free autologous human serum 
and rinsed with Hanks’ Balanced Salt Solution (Gibco).  PBMCs were seeded into 
the gelatin and serum coated flasks for one-hour at 37°C, 5% CO2.  Adherent 
monocytes were washed three times with RPMI and removed from the flasks 
using a mixture of RPMI with 10% FCS and 10 mM EDTA in a 1:1 dilution.  
Isolated monocytes were washed three times with RPMI and plated at 5x105/ml in 
RPMI supplemented with 18% autologous serum for eight days.   
Human embryonic kidney (HEK 293T) cells stably transfected with TLR7 
(HEK/TLR7) or TLR8 (HEK/TLR8) were a generous gift from Dr. Jennifer Wang 
at the University of Massachusetts Medical School in Worcester and were 
maintained in D-MEM with 10% heat inactivated FCS.  HEK/TLR7 was cultured 
in blasticidin at 10 μg/ml and was originally from Invivogen.  Both HEK cell 
lines were subcultured 3 times/week. 
Reverse Transcription Polymerase Chain Reaction (RT-PCR): 
RNA was extracted from cells collected from PBMCs, hepatoma cell lines 
and primary hepatocytes using the RNeasy kits (Qiagen, Valencia, CA), as 
manufacturer instructed.  RNA was DNase (Qiagen) treated on column according 
to manufacturer’s instructions.  Reverse transcription was performed using the 
Reverse Transcription System® from Promega (Madison, WI) according to the 
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manufacturer’s instructions.  PCR products were run on a 1% agarose gel with 
DNA ladders (Roche, #1336045).  The sequences for the primers used are shown 
in Table 2.1. 
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Table 2.1: Primer Sequences of TLR 1-10 and Innate Immune genes for RT-PCR. 
Primer  Forward sequence  Reverse sequence  Product 
Size 
TLR1 5’CTGGTATCTCAGGATGGTGTGC
3’  
5’TTGGAGTTCTTCTAAGGGTATGT
TCC3’  
76 
TLR2  5’GGCCAGCAAATTACCTGTGTG3
’  
5’AGGCGGACATCCTGAACCT3’  67 
TLR3  5’TCCCAAGCCTTCAACGACTG3’  5’TGGTGAAGGAGAGCTATCCACA 
3’ 
68 
TLR4  5’CTGCAATGGATCAAGGACCA3’  5’TTATCTGAAGGTGTTGCACATTC
C3’ 
74 
TLR5  5’TCGAGCCCCTACAAGGGAA3’  5’CACTGAGACTCTGCTATACAAGC
TA3’  
74 
TLR6  5’CTATTGTTAAAAGCTTCCATTT
TGT3’  
5’ACCTGAAGCTCAGCGATGTAGTT
C3’  
187 
TLR7 5’TTACCTGGATGGAAACCAGCT
AC3’  
5’TCAAGGCTGAGAAGCTGTAAGC
TA3’  
72 
TLR8  5’GAGAGCCGAGACAAAAACGTT
C3’  
5’TGTCGATGATGGCCAATCC3’  73 
TLR9  5’TGGTGTTGAAGGACAGTTCTCT
C3’  
5’CACTCGGAGGTTTCCCAGC3’  115 
TLR10  5’GAAAGGTTCCCGCAGACTTG3’  5’TGGAGTTGAAAAAGGAGGTTAT
AG3’  
73 
18S  5’ GGAACTGAGGCCATGATTAA 
3’  
5’ TCGGAACTACGACGGTATCT 3’ 177 
MyD8
8  
5’GAGCGTTTCGATGCCTTCAT3’  5’CGGATCATCTCCTGCACAAA3’ 65 
ISG56  5’TAGCCAACATGTCCTCACAGA
C3’  
5’TCTTCTACCACTGGTTTCATGC3’ 394 
IP-10  5’AGTGGCATTCAAGGAGTACCT3
’  
5’ATCCTTGGAAGCACTGCATCG3’ 289 
ITAC  5’GCTATAGCCTTGGCTGTGATAT
3’  
5’GCCTTGCTTGCTTCGATTTGGG3’ 232 
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MIG  5’TTCAGCAGATGTGAAGGAACT
G3’  
5’AGCATGATGAAATTCAACTGGT3
’ 
389 
TRIF  5’CCAGATGCAACCTCCACTGG3’  5’CTGTTCCGATGATGATTCC3’ 339 
RIG-I  5’CAGTATATTCAGGCTGAG3’  5’GGCCAGTTTTCCTTGTC3’ 389 
MDA-
5  
5’AGTTTGGCAGAAGGAAGTGTC3
’  
5’GGAGTTTTCAAGGATTTGAGC3’ 480 
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All primers were supplied by IDT (Coralville, IA).  The PCR protocol consisted 
of 95°C for 5 min, 30 cycles of 95°C – 30 seconds, 55°C – 30 seconds, 72°C – 1 
minute, and 10 min at 72°C.  PCR was conducted using the BioRad I-cycler. The 
PCR products were separated in agarose gel, stained with 0.01% ethidium 
bromide, detected with UV light. 
Flow Cytometry: 
 Hepatoma cells were detached from plates using trypsin and washed with cell 
culture medium, stained with antibody or fixed and permeabilized with BD 
Cytofix/Cytoperm Kit (BD Biosciences).  Cells were stained with antibodies 
against human TLR1 (Abcam, Cambridge, MA) at 20 μg/ml, TLR2 (Imgenex, 
San Diego, CA) at 5 μl/106 cells, TLR3 (Imgenex) at 20 μg/ml, and TLR7 
antibody (Imgenex) at 5 μg/ml for 1 hour on ice in Cytoperm buffer, washed with 
Cytoperm buffer and then stained with the corresponding secondary antibodies 
either FITC (Santa Cruz Biotechnology, Santa Cruz, CA) at 10 μg/ml or PE 
conjugated antibody 1 μg/ml (Invitrogen, Carlsbad, CA) for 1 hour on ice;  
secondary PE-conjugated or FITC-conjugated antibody alone was used as a 
control.  Cell fluorescence was analyzed using an LSRII (BD Biosciences) flow 
cytometer and FlowJo FACS analysis program (TreeStar, Ashland, OR). 
Nuclear and Cytoplasmic Extraction: 
Hepatoma cells were stimulated for 1 hour with either TNF-α, Pm2, Pm3, 
HCV core, HCV NS3, or HCV NS5a ligands.  Nuclear and cytoplasmic samples 
from stimulated and unstimulated hepatoma cells were extracted by the method of 
Schatzle et al. (232).  Briefly, after stimulation, cells were scraped and washed in 
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ice-cold PBS.  Cells were then resuspended in cold hypotonic buffer A (10 mM 
HEPES (pH 7.9), 10 mM KCl, 0.1 mM EDTA, 0.1 mM EGTA, 1 mM DTT, 1 
mM PMSF, and 10 µg/ml protease inhibitors, aprotinin, antipain, and leupeptin 
(Sigma-Aldrich)) and incubated on ice for 30 min.  Cells were then lysed in 0.6% 
Nonidet P-40 by vortexing for 20 sec.  The lysate was then centrifuged at 12,000 x 
g for 30 sec to pellet the nuclei, and the supernatant was stored at –80°C as the 
cytoplasmic extract.  The nuclear pellet was then resuspended in ice-cold buffer B 
(20 mM HEPES (pH 7.9), 400 mM KCl, 1 mM EDTA, 1 mM EGTA, 1 mM DTT, 
1 mM PMSF, and 20% glycerol).  All tubes were kept on a shaker at 4°C for 30 
min. The lysate was then centrifuged at 12,000 x g for 15 min and the supernatant 
was stored at –80°C as the nuclear extract. Protein content was determined in both 
the cytoplasmic and nuclear extract by the Bio-Rad Dye Reagent assay.  
Electrophoretic Mobility Shift Assay (EMSA): 
Nuclear extracts were used for EMSA analysis.  A consensus dsNF-κB 
oligonucleotide (5'-AGTTGAGGGGACTTTCGC-3') was used to bind NF-κB.  
End-labeling was accomplished by treatment with T4 polynucleotide kinase in the 
presence of [γ-32P]ATP (DuPont-NEN).  Labeled oligonucleotide was purified on 
a polyacrylamide copolymer column (Bio-Rad).  Nuclear protein (5 µg) was 
added to a binding reaction mixture containing 20 mM HEPES (pH 7.9), 50 mM 
KCl, 0.1 mM EDTA, 1 mM DTT, 5% glycerol, 200 µg/ml BSA, 2 µg of 
polydeoxyinosinic-polydeoxycytidylic acid, and 50,000 cpm of γ-32P-labeled NF-
κB oligonucleotide.  Samples were incubated at room temperature for 30 min.  All 
reactions were run on a 6% polyacrylamide gel, dried overnight, and the gel was 
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exposed to x-ray film at –80°C overnight.  For the cold competition reaction, a 20-
fold excess of specific unlabeled double-stranded probe was added to the reaction 
mixture before adding the labeled oligonucleotide.  
Enzyme-Linked Immunosorbent Assay (ELISA): 
 Hepatoma, primary hepatocytes, HEK/TLR7, HEK/TLR8, and hMDM cells 
were stimulated for 10 hrs or for a time course up to 144 hours with TLR-specific 
ligands or HCV core or NS3 recombinant proteins.  Cell culture supernatants 
were collected and analyzed using cytokine specific ELISAs (IL-6 and IL-8 
ELISAs from BD Bioscience (San Jose, CA), IFN-α (limit of detection =10 
pg/ml) and IFN-β (limit of detection=25 pg/ml) ELISA from PBL Interferon 
Source (Piscataway, NJ)), all performed according to the manufacturer’s 
instructions. 
Statistical analysis: 
 Statistics were calculated by student’s t-test using EXCEL with a p-value less 
than 0.05 as statistical significance.  Human hepatocytes were from one individual 
performed in three or one independent setting as stated in figure legends.   
PART 2: Toll-like receptors 1 and 6 are both involved in TLR2-mediated 
macrophage activation by Hepatitis C Virus core and NS3 proteins 
Reagents: 
 S. aureus peptidoglycan (PGN) was from Fluka (Milwaukee, WI). HCV NS3 
and core proteins were fused with E coli derived β-galactosidase at the N-
terminus and had >95% purity as evaluated by SDS-PAGE.  Further purification 
of recombinant proteins was performed by S-Sepharose-Ceramic Hydroxyapatite-
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Affinity purification by Biodesign.  β-galactosidase was expressed and purified 
identically to HCV core and NS3 proteins (kindly provided by Biodesign), and 
was used as a control where indicated.  To confirm there were no immunogenic 
affects from β-galactosidase we stimulated cells with β-gal alone.   
Cells: 
HEK 293T cells stably transfected with TLR2/YFP (HEK/TLR2) were 
maintained in D-MEM with 10% heat inactivated FCS and selective antibiotics 
and subcultured 3 times/week.   
C57BL/6J (wild type), TLR2, TLR1, TLR4 and TLR6 knockout mice and 
TLR4 mutant mice were a gift from Dr. Robert Finberg at the University of 
Massachusetts Medical School, Worcester, MA.  TLR4 mutant mice were 
C3H/HeJ mice that have a spontaneous point mutation in the intracellular domain 
of TLR4 that blocks LPS signaling.  Mice were injected with a 4% thioglycollate 
medium intraperitoneal and peritoneal macrophages were extracted from 
peritoneal exudates five-days later.  Mouse macrophages were plated in 96 well 
plates (BD Biosciences, Franklin Lakes, NJ) at 106/ml.  
Small Interfering RNA: 
TLR2, TLR1, TLR6, and control siRNA oligonucleotides (Cat. 1027280) 
were purchased from Xeragon (Valencia, CA).  The full mRNA sequence was 
located from GeneBank and siRNA sequences were identified as 21-nucleotides 
starting with AA and ended with TT and were chosen after the first 150 base pairs 
of the full mRNA sequence.  Sequences with G/C content between 30 to 70% 
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were used.  Sequence alignment tests confirmed specificity to corresponding 
TLR.   
HEK/TLR2 cells were plated in a 24 well plate at 106/ml and grown to 
yield 70% confluency.  SiRNAs (final concentration 300 nM/well) were 
combined with Mirus TransIT transfection reagent and Opti-MEM medium for 15 
minutes.  The culture medium was changed prior to transfection and the siRNA 
mix was added to each well and incubated for eight hrs at 37°C.  After 
transfection, 1 ml of fresh culture medium was added to each well and the cells 
were grown for an additional time up to 72-96 hours.   
Human monocyte-derived macrophages (hMDM) were transfected with 
siRNAs using Lipofectamine 2000.  Briefly, 3 µls of Lipofectamine 2000, 350 µl 
D-MEM, and 60 pmol of siRNA/well were incubated for 15 min at room 
temperature.  The macrophages were washed with serum-free D-MEM and 
incubated at 37°C, 5% CO2 for three hours with siRNA transfection mixture as 
described above.  After incubation, the cells were washed with serum-free D-
MEM and maintained in RPMI with 18% autologous serum for up to 72-96 hours.  
Knockdown of a specified gene was confirmed by Real Time PCR analysis for 
the mRNA expression and by Western Blot analysis for protein expression. 
Protein quantification by Western Blot: 
Twenty-four and seventy-two hours after siRNA transfection the cells 
were counted and lysed for 10 min on ice with lysis solution: [1% NP40, 0.5% 
docetaxel, 1.5 mM NaCl, 0.5 M EDTA, Complete Mini® Protease Inhibitor 
Cocktail (Roche)].  The lysate was spun at 4°C for 10 min at 14,000 rpm, 
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collected and mixed with SDS sample buffer.  Protein samples were heated at 
95°C for 2 minutes, loaded onto a 10% SDS-PAGE and transferred to a 
nitrocellulose membrane.  Precision Plus Protein standard Bio-Rad (Hercules, 
CA) was used for the molecular weight ladder.  Membranes were blocked 
overnight with 5% non-fat milk in PBS, and then probed with anti-TLR6 (Zymed, 
San Francisco, CA) or anti-β-actin (Abcam, Cambridge, MA) antibodies at 
1:10,000 dilution in PBS for 1hr at room temperature.  Secondary HRP-labeled 
goat anti-mouse antibody (Santa Cruz, Santa Cruz, CA) and enhanced 
chemiluminescence (LumiGlo kit Cell Signaling Technology (Danvers, MA) 
were employed to identify the immunoreactive bands. The densitometry analysis 
of the immunoreactive bands was performed using the Fuji UVP system and 
LabWorks program. 
Reverse transcription and polymerase chain reaction: 
RNA was extracted from cells collected 48 and 72 hrs after siRNA 
transfection using the RNeasy kits (Qiagen, Valencia, CA), as manufacturer 
instructed.  Reverse transcription was performed using the Reverse Transcription 
System® from Promega (Madison, WI) according to the manufacturer’s 
instructions.  The sequences for the primers used are shown in Table 2.2.  Primers 
for TLR2, TLR1, and TLR6, were all supplied by IDT (Coralville, IA).  18S 
primers were from Ambion (Austin, TX).  The PCR protocol consisted of 95°C 
for 5 min, 30 cycles of 95°C – 30 seconds, 55°C – 30 seconds, 72°C – 1 minute, 
and 10 min at 72°C.  PCR was conducted using the BioRad I-cycler. The PCR 
products were separated in an agarose gel, stained with 0.01% ethidium bromide, 
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detected with UV light and quantified using the Fuji UVP system and LabWorks 
program. 
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 Table 2.2: Primer Sequences for TLRs recognizing HCV proteins using RT-PCR 
Primer  Forward Sequence  Reverse Sequence  Product 
Size 
TLR1 5’-GGGTCAGCTGGACTTCAGAG-3’  5’-AAAATCCAAATGCAGGAACG-3’   214 
TLR2  5’-ACTCAGGAGCAGCAAGCAC-3’  5’-ATCAGCAGGAACAGAGCACA-3’  173 
TLR6  5’-GAACATGATTCTGCCTGGGT-3’  5’-GCTGTTCTGTGGAATGGGTT-3’  282 
18S  5’-GGAACTGAGGCCATGATTAA-3’  5’-TCGGAACTACGACGGTATCT-3’  177 
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Flow cytometry analysis: 
 HEK/TLR2 cells were detached from plates using trypsin and washed with 
cell culture medium.  Control and siRNA-treated cells were incubated with anti-
human TLR2 antibody (a kind gift from Dr. Robert Finberg, University of 
Massachusetts Medical School, Worcester, MA) and secondary APC-conjugated 
antibody (Caltag Laboratories, Burlingame, CA).  APC-conjugated antibody 
alone was used as a background control.  Cell fluorescence was analyzed using an 
LSR II (BD Biosciences) flow cytometer and FlowJo FACS analysis program 
(TreeStar, Ashland, OR). 
Cytokine quantification by ELISA: 
 SiRNA-transfected cells and mouse peritoneal macrophages were stimulated 
for 10 hrs with TLR-specific ligands or HCV core or NS3 recombinant proteins.  
Cell culture supernatants were collected and analyzed using cytokine specific 
ELISAs (IL-6, IL-8, and TNF-α ELISAs from BD Bioscience (San Jose, CA), IL-
10 ELISA from eBioscience (San Diego, CA)), all performed according to the 
manufacturer’s instructions. 
Statistical analysis: 
All data derived from cell lines were analyzed with t-test, those from 
mouse macrophages employed ANOVA and those from human monocyte-derived 
macrophages with non-parametric Wilcoxon statistical analysis methods. A 
p<0.05 was considered statistically significant.  Statistics were calculated by 
using EXCEL.   
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PART 3: Impaired expression and function of Toll-like receptor 7 in 
Hepatitis C virus infection in human hepatoma cells  
Reagents:  
DMEM, Dulbecco’s Modified Eagle Medium and NEAA, nonessential 
amino acids, Geneticin (G418) and TrypLE Express were from Gibco (Grand 
Island, NY) and FCS, fetal calf serum, was from Hyclone (Logan, UT).  
Ciprofloxacin was from CellGro (Herndon, VA).  IFNα, Actinomycin D and 
Alpha amanitin were from Sigma Aldrich (St. Louis, MO) and R837 was from 
Invivogen (San Diego, CA). 
Cells: 
All cells were grown in 5% CO2 at 37°C and passed at 75% confluency.  
Human hepatoma cell lines, Huh7 and Huh7.5 were maintained in DMEM with 
10% heat inactivated FCS, 1% NEAA and 500 μg/ml Ciprofloxacin.  HCV stable 
cell lines FL, generated on the Huh 7.5 background, and BB7, generated on the 
Huh7 background, were maintained in DMEM with 10% FBS, 1% NEAA, 500 
μg/ml Ciprofloxacin and either 750 μg/ml G418 or 500 μg/ml G418.  All four cell 
lines were gifted from Dr. Charlie Rice at the Rockefeller University (New York, 
NY).  JFH-1 plasmid was a generous gift from Dr. Takaji Wakita at the National 
Institute of Infectious Disease (Tokyo, Japan).  The JFH-1 cell line, generated on 
the Huh7.5 background, was propagated by following the methods outlined 
previously (233) and briefly stated here.  JFH-1 plasmid was transformed into 
JM109 cells (Promega) and grown overnight in LB broth with ampicillin.  
Plasmids were extracted by a Maxiprep kit from Qiagen and cut with Xba1 from 
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New England Biolabs, (Ipswich, MA).  RNA transcription was performed using 
MEGAscript T7 kit by Ambion, Austin, TX.  Purified RNA was electroporated 
into Huh7.5 cells using Gene Pulser II™ apparatus by Bio-Rad (Hercules, CA).  
All cells were grown in 5% CO2 at 37°C and passed at 75% confluency.   
Quantitative Real Time Polymerase Chain Reaction: 
RNA isolated from HCV patients’ liver tissue samples were obtained from 
Dr. Gyongyi Szabo (University of Massachusetts Medical School).  RNA was 
isolated using the RNeasy Kit (Qiagen) for tissue samples according to 
manufacturer’s protocols and subjected to DNase treatment (Qiagen) during 
isolation.  For analysis by quantitative PCR, cellular RNA was extracted with 
RNeasy Kit (Qiagen, Valencia, CA) and on column DNase (Qiagen) treatment 
was performed according to manufacturer’s instructions.  Complementary cDNA 
was transcribed with the Reverse Transcription System (Promega, Madison, WI) 
according to manufacturer’s instructions.  TLR7, TLR5 and glyceraldehyde 3-
phosphate dehydrogenase (GAPDH) quantification was performed by real-time 
PCR (QRT-PCR) with Sybr Green Master Mix (Eurogentec, San Diego, CA) 
according to manufacturer’s instructions; HCV and GAPDH was assessed with 
Taqman Universal PCR Master Mix (Applied Biosystems, Foster City, CA), all 
on the Eppendorf Realplex4 Mastercycler (Eppendorf, Westbury, NY). β-actin 
was used for RNA stability experiments as it was more stable throughout the 24 
hour time course than GAPDH.  The sequences of the specific primers are listed 
in Table 2.3.  TLR7 and TLR5 primer sequences are listed in Table 2.1.  The delta 
delta ct method was used to calculate fold change in all quantitative PCR graphs. 
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Table  2.3: Primer Sequences for HCV Quantitative Real Time-PCR 
Primer  GAPDH  HCV  β-actin (232bp) 
Sense  5’-
TGCCTTCTTGCCTCTT
GTCT-3’ 
5' NTR: 5'-
CCTCTAGAGCCATAGTG
GTCT-3’ 
5’-
GCGGGAAATCGTGCGT
GACAT-3’ 
Anti-
sense 
5’-
GGCTCACCATGTAGC
ACTCA-3’ 
5'-
CCAAATCTCCAGGCATT
GAGC-3' 
5’-
GATGGAGTTGAAGGTA
GTTTC-3’ 
Taqman 
probe 
FAM-
TTTGGTCGTATTGGG
CGCCTGG-BHQ1 
FAM-
CACCGGAATTGCCAGG
ACGACCGG-BHQ1 
Not Applicable 
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Western Blot: 
For assessment by Western Blot, cells were lysed for 10 min on ice with 
1% Nonidet P-40, 0.5% docetaxel, 1.5 mM NaCl, 0.5 M EDTA, Complete Mini 
protease inhibitor cocktail (Roche, Indianapolis, IN) and the lysate was spun at 
4°C for 10 min at 14,000 rpm. Equal amounts of total cellular proteins from each 
experimental group were mixed with 4x SDS-containing loading buffer, heated at 
95°C for 5 min, separated on 10% SDS-PAGE, and transferred to a nitrocellulose 
membrane. Precision Plus protein standard (Bio-Rad, Hercules, CA) was used as 
a molecular weight ladder. Membranes were blocked overnight with 5% nonfat 
milk in PBS and probed with anti-NS5A antibody 1:500 (a generous gift from Dr. 
Charlie Rice) or anti-β-actin (Abcam, Cambridge, MA) 1:10,000.  Secondary 
HRP-labeled goat anti-mouse antibody (Santa Cruz Biotechnology, Santa Cruz, 
CA) and ECL [LumiGlo kit, Cell Signaling Technology (Danvers, MA)] were 
used to identify the immunoreactive bands.  
Flow Cytometry: 
For flow cytometry analysis, cells were detached from plates using cell 
stable TrypLE Express, washed, fixed and permeabilized with BD 
Cytofix/Cytoperm Kit (BD Biosciences).  Cells were stained with anti-human 
TLR7 antibody (Imgenex, San Diego, CA) 1:100 for 1 hour on ice in Cytoperm 
buffer, washed with Cytoperm buffer and then stained with secondary anti-mouse 
PE conjugated antibody 1:1000 (Invitrogen, Carlsbad, CA) for 1 hour on ice;  
secondary PE-conjugated antibody alone was used as a control.  Cell fluorescence 
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was analyzed using an LSRII (BD Biosciences) flow cytometer and FlowJo 
FACS analysis program (TreeStar, Ashland, OR).   
Immunofluorescence: 
For immunofluorescence, cells were plated at 105/ml on 4 well BD Falcon 
CultureSlides (BD Biosciences, San Jose, CA) and grown overnight in 37°C, 5% 
CO2.  Cells were washed with PBS and fixed on slide with methanol:acetone 1:1 
mix for 10 minutes.  Slides were dried, rinsed with PBS, blocked for 1 hour with 
10% human serum in PBS and probed with anti-HCV core antibody 1:250 
(Affinity BioReagents, Golden, CO) overnight at 4°C.  Slides were washed with 
0.5% Tween 20-PBS for 30 min followed by AlexaFluor 568 goat anti-mouse IgG 
antibody 1:1000 (Invitrogen) for 1 hour.  During the final wash step DAPI (2 
μg/ml) was added for 10 minutes.  Slides covered with a glass coverslip using 
ProLong Antifade kit (Invitrogen) and analyzed for fluorescence using a Leica 
DM IRE2 confocal microscope.  
RNA stability: 
 RNase inhibitors, alpha-amanitin and actinomycin D, were added to cell 
culture media at a concentration of 10 μg/ml and 2 μg/ml for up to 24 hours.  Cell 
RNA samples were extracted at 0, 2, 4, 8 and 24 hours.  QRT-PCR was run on 
RNA samples using TLR7, HCV, and β-actin primers.   
ImageStream: IRF7 Nuclear Translocation analysis  
Hepatoma control and HCV replicating cells were plated at 8x105/ml and 
grown overnight in 5% CO2 37°C and stimulated with R837 (10 μg/ml) for a time 
course up to 4 hours.  Cells were fixed and permeabilized as described for the 
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flow cytometric analysis and stained for IRF7 (Santa Cruz Biotechnology, Santa 
Cruz, CA) 1:50 for 1 hour on ice.  Cells were stained with secondary anti-mouse 
IgG conjugated with Alexa Fluor 488 (Invitrogen) 1:1000 for 1 hour on ice, then 
with 5 μM DRAQ5 (Biostatus Limited, Leicestershire, UK) for nuclear staining.  
Image files of 10,000 events were collected for each sample using the 
ImageStream system (Amnis, Seattle, WA) and analyzed using IDEAS software 
(Amnis). Single cells were identified by in-focus gating on IRF7 or DRAQ5 
fluorescent events with high nuclear aspect ratios (minor to major axis ratio, a 
measure of circularity) and high nuclear contrast (as measured by the Gradient 
Max feature). Nuclear localization of IRF7 was measured using the similarity 
score, which quantifies the correlation of pixel values of the nuclear and IRF7 
images on a per-cell basis (234). If IRF7 is nuclear, the two images will be similar 
and have large positive values. If it is cytoplasmic, the two images will be anti-
similar and have large negative values. Events with positive values had visually 
apparent nuclear distributions of IRF7 and were gated to quantify the percentage 
of cells within the hepatoma population with nuclear-localized IRF7 (234) 
Statistical analysis: 
 Statistics were calculated by student’s t-test using EXCEL with a p-value less 
than 0.05 as statistical significance.   
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CHAPTER III 
Characterization of TLRs in hepatocytes. 
 There are a number of host factors that are affected by HCV either directly or 
indirectly.  Since the discovery of a cell culture model that supports HCV 
infection, intense research is ongoing.  Previous groups have uncovered a number 
of host innate immune factors that are manipulated by HCV proteins (235, 236).  
HCV core and NS3 proteins were shown to activate TLR2 in human monocytes, 
HEK/TLR2, and murine peritoneal macrophages (79).  HCV E2 binds to CD81 
causing inhibition of NK cell activation (153).  To further investigate innate 
immune mechanisms activated by HCV in hepatocytes, we hypothesized that both 
hepatoma and primary hepatocytes express functional TLR1, TLR6, and TLR7 
that may be involved in the recognition of HCV.   
Identification of TLR RNA in Hepatocytes 
Previously, a number of innate immune receptors including some TLRs 
were thought to be exclusive to specific cell types (237).  In particular, TLR7, 
TLR8, and TLR9 were thought to be restricted to dendritic cells (238, 239).  To 
investigate our hypothesis and establish TLR expression, we used hepatoma cell 
lines Huh7 and Huh7.5 and purified primary hepatocytes to determine the TLR 
mRNA expression levels by RT-PCR (Figure 3.1).  Using primers shown in Table 
1, directed towards TLRs 1-10 and other various innate immune factors, we 
determined that hepatoma cells express almost all TLRs except for TLR10 in both 
cell lines and TLR8 in Huh 7.5.  PBMCs express all ten TLRs and were thus run 
alongside the hepatoma cells as a control for TLR expression.  No RT controls 
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were run alongside all cell types to ensure no contaminating products contributed 
to expression.  Because hepatoma cells are transformed hepatocytes and could 
have changes in cellular RNA expression, we used primary hepatocytes to 
confirm that TLR expression is similar in both transformed and untransformed 
cell types (Figure 3.1B).  Primary hepatocytes express very similar levels of TLRs 
as the hepatoma cells.  The major difference is that TLR10 and TLR8 are 
expressed in primary hepatocytes compared to hepatoma cells.  Primary 
hepatocytes also express a variety of innate immune factors associated with TLRs.  
The differences in TLR8 and TLR10 expression between hepatoma cells and 
hepatocytes may indicate possible functional variations when responding to HCV.  
Band sizes vary due to the time agarose gels were run for.  Figure 3.1A and 
Figure 3.1B upper half, were run for a short time period shown by their condensed 
DNA ladders and thus the sizes of the bands are more condensed, while Figure 
3.1B lower half was run for a longer period of time resulting in much more space 
aliquoted between the band sizes.  No RT controls were run for every PCR in this 
figure and all subsequent figures with PCR to ensure no contaminating products.   
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Figure 3.1: Messenger RNA expression of Toll-Like Receptors in human hepatoma 
cell lines and primary hepatocytes.  (A.) Reverse Transcription PCR was performed 
showing TLR 1-10 expressions from hepatoma cell lines, Huh7 and Huh7.5, and 
PBMCs used as a control for TLR expression.  18S was used as an experimental 
control to ensure proper PCR technique. DNA ladder is also shown with basepair 
markers indicated with arrows.  (B.) TLR expression on pure primary human 
hepatocytes is representative of two independent experiments.  Targets of both 
TLR-mediated pathways and other innate immune receptors were also performed 
shown in the bottom half of (B).  No RT controls are shown next to the DNA ladder 
for each cell type.  Figures shown are representative of three independent 
experiments. 
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Possible HCV Targets within the TLR Family: TLR2/1, TLR2/6, and TLR7 
HCV targets specific TLRs to induce either an immune response or 
immune escape (235, 236).  Others have reported TLR2 immune activation (79) 
and TLR3-mediated pathway inhibition by HCV proteins (106).  TLR2 immune 
activation was not fully characterized as TLR2 heterodimerizes with TLR1 or 
TLR6, thus we examined the activation of TLR2 and its heterodimers.  TLR3 is a 
viral recognition receptor in a small family of TLRs contained in the endosome 
(240).  TLR3-mediated pathway inhibition was thoroughly described and so we 
decided to investigate other viral recognition receptors (106).  Since HCV is a 
single stranded RNA virus, we decided to investigate TLR7, a single stranded 
RNA viral recognition receptor.  TLR2, TLR1, TLR6 and TLR7 mRNA was 
expressed in both hepatoma and primary hepatocytes (Figure 3.1).   
Protein Receptor Expression of TLR2 Heterodimers and TLR7 
We next looked into the protein expression levels either on the cell surface 
or within the cell using flow cytometry.  Previous groups have reported protein 
expression of TLR3 within hepatoma cells and we confirmed these results in 
Figure 3.2 (240).  There are moderate levels of TLR1 on the cell surface 
compared to high protein expression of TLR2 both on the cell surface and within 
the cell.  There is a slight tail of increased fluorescent intensity to the right of the 
histogram of TLR1 expression which could be from variations in staining.  There 
was no expression of TLR7 on the cell surface but moderate expression levels 
within the cell.  Flow cytometry antibodies specific for TLR6 were not optimized 
at that time and so we do not show TLR6 protein expression.  These results 
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confirm the presence, both RNA and protein, of TLR2, TLR1 and TLR7 in human 
hepatoma cell lines.   
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Figure 3.2: TLR protein expression levels in human hepatoma cell lines.  Human 
hepatoma cells were either fixed or permeabilized and fixed for flow cytometry 
analysis.  TLR specific antibodies stained cell surface and intracellularly, where 
indicated, on Huh7 and Huh 7.5 cells.  Grey shaded histogram represents the 
corresponding secondary antibody control.  Data shown are representative of three 
separate experiments.  
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TLR Functional Confirmation in Hepatoma Cells: Activation of NF-κB 
In mice, TLR8 RNA and protein is expressed yet reported non-functional 
(241).  Non-functional receptors may not be an active target of HCV; therefore to 
confirm functionality in the TLR2 heterodimer complexes and TLR7 we 
stimulated hepatocytes with TLR2 heterodimer and TLR7 specific ligands.   
 On unstimulated hepatoma cells, we observed a high background of IL-8 and 
IL-6 cytokines which upon treatment with TLR2 or TLR7 ligands did not induce 
a significant increase (data not shown).  Therefore, we tested the function of these 
receptors by investigating the NF-κB nuclear activation after ligand stimulation 
using electrophoretic mobility shift assays.  NF-κB is a major transcription factor 
that is activated upon numerous stimulations such as TLR ligand stimulations (79, 
191).  Activation of this factor elicits a variety of pro- and anti-inflammatory 
cytokines and chemokines such as IL-6 and IL-8.  EMSAs were performed using 
nuclear extracts from Huh7 (Figure 3.3B) or Huh7.5 (Figure 3.3A) cells 
stimulated for one hour with TLR specific ligands.  Using TLR2/1, Pm3, or 
TLR2/6, Pm2, specific ligands (242), we found more NF-κB activation with 
ligands specific to TLR2/6 compared to TLR2/1, although both ligands activated 
NF-κB.  After one hour I did not see a measurable increase from R848 stimulated 
cells in NF-κB activation compared to the control (data not shown) using EMSA.  
These results show functional TLR2, TLR1 and TLR6 receptors in Huh7 and 
Huh7.5 cells.   
 Recombinant HCV proteins, core and NS3, can elicit a cellular response in 
epithelial and immune cells (79, 108).  It is not known whether hepatocytes react 
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to HCV protein administration, therefore we investigated whether hepatoma cells 
activate NF-κB after a one hour stimulation using recombinant HCV core, NS3 
and NS5A proteins (Figure 3.3).  We found that both Huh7 and Huh7.5 cells 
respond to HCV core and NS3 stimulation.  The NS5A response in Huh7.5 cells 
showed a small amount of NF-κB activation while in the Huh7 cells it was 
relatively weak compared to the media control.  These results show that despite 
the lack of cytokine production from hepatoma cell lines that would be released 
into the media, these cells are activated by TLR2 heterodimer ligands and HCV 
proteins.   
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Figure 3.3: NF-κB activation in hepatoma cell lines by electrophoretic mobility shift 
assay.  (A.) Huh7.5 and (B.) Huh7 cells were stimulated with the indicated 
concentrations for one hour by TNF-α (stimulation control), Pm2 (TLR2/6 ligand), 
Pm3 (TLR2/1 ligand), HCV core, HCV NS3, HCV NS5A and plain media as a 
negative control.  EMSA was used to study the protein-DNA interaction for the NF-
κB complexes in nuclear extracts from hepatoma cell lines.  TNF-α is a positive 
stimulation control for NF-κB activation.  The media alone lane were cells that did 
not have any stimulants and controlled for excess baseline activation of NF-κB.  
There was no excess baseline seen in the media control lanes.  Competition lanes 
were used to identify NF-κB complexes.  Competition lanes contained cold 
(unlabeled) oligonucleotide sequence that competitively bound to NF-kB 
oligonucleotide sequence in the TNF-α stimulated sample and was administered 20 
minutes before labeled oligonucleotide was added to the extracts.  Densitometry 
included both upper and lower bands.  Density graphs are shown below and 
correspond to the bands directly above the bars.  Data shown is representative of 
four independent experiments. 
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Primary Hepatocytes Show Cytokine Production when stimulated with HCV 
Proteins 
Since hepatoma cells are not an exact representation of how TLRs 
function in primary hepatocytes, we investigated cellular activation using primary 
human hepatocytes obtained from Cambrex.  Unlike hepatoma cell lines, primary 
hepatocytes do produce measurable amounts of cytokines in media upon 
stimulation.  The caveat to using human hepatocytes is the expense in obtaining 
them, therefore where noted in the figures, most human hepatocyte experiments 
were completed only using one individual either in triplicates or singlets.  We 
stimulated the cells for ten hours with HCV proteins, core and NS3, and used 
purified lipopolysaccharide (pLPS), a TLR4 specific ligand, as a positive control.  
We ran enzyme-linked immunosorbent assays (ELISAs) for IL-6 and IL-8.  Both 
HCV core (p<0.002) and NS3 (p<0.047) produced a moderate IL-6 response, 
200-300 pg/ml, after ten hours (Figure 3.4A) which was significant compared to 
the media control.  This response was acute showing the peak levels, around 550 
pg/ml, at ten hours and diminished in half after three days and back to control 
levels after 6 days (Figure 3.4B).  We observed a more substantial and significant 
IL-8 response, around 3000 pg/ml, when stimulated with the same proteins after 
ten hours (Figure 3.4C).  Unlike the rapid IL-6 response, the IL-8 response was 
much slower, peaking, between 25,000 and 30,000 pg/ml, after 3 days and 
sustaining the response up to 6 days (Figure 3.4D).  These results show that 
primary hepatocytes do respond when stimulated with HCV core and NS3 
proteins and the response is both a rapid and slow production of cytokines.  Beta-
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galactosidase was run as a negative control in Figure 4.2 to assure that β-gal 
fusion to HCV core or HCV NS3 proteins was not contributing or interfering with 
cellular cytokine production.  There was no contribution by β-gal to cytokine 
production in either primary macrophages or HEK/TLR specific cells. 
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Figure 3.4: IL-6 and IL-8 response in primary human hepatocytes to HCV proteins.  
(A.) IL-6 and (C.) IL-8 were measured with ELISA after a ten hour stimulation with 
HCV proteins, core or NS3, or pLPS with the indicated concentrations.  Data are 
shown as an average + SD pg/ml of n=3 replicate wells experiments from one non-
HCV infected control.  P-values compared with the media control were calculated 
using the student’s T-test.  Time courses of (B.) IL-6 and (D.) IL-8 were measured 
with ELISA using the same stimulations as in (A.) and (C.) but were performed with 
one non-HCV infected individual of n=1 experiment.  Data are shown with different 
non-HCV control hepatocytes from (A.) and (C.). 
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Examining Type 1 IFN Response in Hepatocytes 
 HCV infection is treated with a combined therapy of pegylated IFN-α and 
ribavirin (35, 37).  Specific cell types in the liver produce Type 1 IFNs upon 
activation from cellular factors, such as TLR7 or TLR3 (179, 181, and 195).  
Unlike TLR3 where IFN-β is the primary product after stimulation, IFN-α is the 
main product of the activated TLR7 IFN-mediated pathway (199, 243).  Earlier 
reports have already identified inhibition of Type 1 IFN production by HCV 
proteins, thus showing the viral defense mechanisms against anti-viral products 
(106, 171, 172, and 178).  Since IFN-α is involved in combating HCV infection, 
we investigated whether primary hepatocytes and representative cell types in the 
liver could produce Type 1 IFNs using a TLR7/TLR8 specific ligand, R848.   
 We used pure human hepatocytes and human monocytes derived macrophages 
(hMDMs) which are similar to Kupffer cells, hepatic macrophages.  We measured 
IFN-α and IFN-β by ELISA in all cell types (Figure 3.5A, B and data not shown).  
Human hepatocytes barely produced the detectable limit of IFN-β after 20 hours 
of stimulation (data not shown); hMDMs elicited a much larger increase of IFN-β 
compared to hepatocytes when stimulated with R848 (Figure 3.5A).  This 
suggests that the primary cell type to produce IFN-β in the liver could be Kupffer 
cells..  Unlike IFN-β, human hepatocytes did not produce any IFN-α above the 
limit of detection of 12.5 pg/ml (data not shown).  The hMDMs showed a much 
reduced amount of IFN-α production compared to its IFN-β production but was 
measurable above the limit of detection (Figure 3.5B).  These results show that 
human hepatocytes do not produce measurable amounts of extracellular IFN-α 
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and very little IFN-β when stimulated with R848 up to 144 hours (data not 
shown) while human macrophages do produce both IFNs.   
 TLR7 stimulation results in activation of two separate pathways: production 
of inflammatory cytokines through NF-κB transcription factor or Type 1 IFN 
production through interferon regulatory factor (IRF) 7 (179, 243, 228, and 229).  
In Figure 3.5A and 3.5B we show the limited Type 1 IFN response from 
hepatocytes.  To investigate the other pathway in hepatocytes, we stimulated cells 
with R848 during a time course and measured IL-6 (Figure 3.5C) and IL-8 
(Figure 3.5D) levels using ELISA.  Primary hepatocytes showed a similar pattern 
of cytokine induction when stimulated with HCV proteins or R848.  IL-6 levels 
after R848 treatment were rapid in response after ten hours quickly diminishing 
after 3 days and showed similar quantities compared with stimulation using HCV 
proteins.  IL-8 levels, on the other hand, were induced after ten hours yet slowly 
peaked by 3 days, showing the same pattern of induction as when stimulated with 
HCV proteins.  The only difference between the two stimulants (HCV proteins vs 
R848) was the order of magnitude; HCV proteins induced a larger cytokine 
production compared to R848.  These results show that the TLR7 receptor in 
human hepatocytes previously thought to be rare in expression and dysfunctional, 
is fully functional and does elicit a response to ligand stimulation. 
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Figure 3.5: Cytokine response from TLR7/8 specific ligand in primary hepatocytes 
and macrophages.  (A.) IFN-β or (B.) IFN-α levels were measured by ELISA after 
stimulation with R848, TLR7/8 specific ligand, for the indicated time periods from 
human monocytes derived macrophages, hMDMs.  (C.) IL-6 and (D.) Il-8 was also 
measured by ELISA after stimulation with R848 from primary hepatocytes.  Data is 
shown as an average + SD of n=3 independent experiments or for primary 
hepatocytes n=1 experiment.  Primary hepatocytes originated from one non-HCV 
infected individual performed in one experiment.  P-values compared with the 
media control were calculated using the student’s T-test.   
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Chapter Summary 
 Human hepatocytes are the primary host for HCV infection which can lead to 
liver failure.  Although many advances have been made in HCV research, there 
are still a number of unknown areas of interest.  The diverse innate immune 
reaction occurring in HCV infected patients has prompted many to identify 
factors responsible for chronic HCV.  Though there are many immune cell types 
in the liver responsible for yielding inflammatory and IFN cytokines, the majority 
of cells are hepatocytes, host to HCV.  We have studied the identity and function 
of specific TLRs in hepatocytes which until now was unknown.  Others have 
previously shown that HCV proteins stimulated peripheral blood mononuclear 
cells in healthy human controls, for the first time we have shown that these 
proteins can also stimulate hepatocytes.   
 TLR RNA was expressed in hepatoma cell lines, Huh7 and Huh7.5 with 
absence of expression in TLR8 and TLR10 in Huh7.5 cells compared to both 
Huh7 and PBMC controls.  Primary human hepatocytes also showed TLR 
expression without absence of TLR8 or TLR10.  Primary hepatocytes additionally 
showed expression of various innate immune factors except for RIG-I.  TLR2 was 
previously reported to become activated by HCV proteins, yet this activation was 
not identified in hepatocytes, the main cell type in the liver.  TLR7 was identified 
as a viral recognition receptor of single stranded RNA viruses and agonists were 
involved in reduction of HCV replication.  Therefore, we investigated receptor 
surface and intracellular levels of the TLR2 and its heterodimers, and TLR7.  We 
found measurable amounts of TLR2, TLR1, and TLR7 within the cell.   
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 Next, we tested the function of these cells in hepatoma cell lines and primary 
hepatocytes.  We found NF-κB activation in hepatoma cell lines upon TLR2/1 or 
TLR2/6 specific ligand stimulation, yet did not find measurable amounts using 
R848.  We were able to measure IL-8, IL-6, and Type 1 IFN cytokine production 
from activated primary hepatocytes and found that the TLR7 and TLR4 receptor 
is functional.  We also found HCV proteins, core and NS3, activated both 
hepatoma cell lines and hepatocytes, producing a large amount of inflammatory 
cytokines.  These results show that hepatocytes do respond to TLR ligands and 
HCV proteins suggesting that they are not only a host to HCV but could 
contribute demonstrably to innate immune functions against HCV.   
68 
 
CHAPTER IV 
Toll-like receptors 1 and 6 are both involved in TLR2-mediated macrophage 
activation by Hepatitis C Virus core and NS3 proteins 
Previous work showed that HCV proteins, core and NS3, stimulated 
human monocytes, TLR2 expressing HEK cells, and mouse peritoneal 
macrophages in a TLR2-specific manner and induced production of TNF-α and 
IL-10 (79).  HCV infection targets the liver where Kupffer cells, resident liver 
macrophages, are the major cell type involved in innate immune pathogen 
surveillance and pro-inflammatory cytokine production.  Similar to human 
monocytes and monocyte-derived macrophages (hMDMs), Kupffer cells express 
TLR2, TLR1, TLR6, TLR4, and TLR9 (207, 244).  Purified human or mouse 
Kupffer cells are very difficult to acquire, therefore to investigate the effects of 
HCV proteins on these cells we used hMDMs and mouse peritoneal macrophages 
which are within the same family as Kupffer cells.   
HCV proteins cause dose dependent inflammatory cytokine production in 
hMDMs 
We found that normal human monocytes and hMDMs express TLR2, 
TLR1 and TLR6 (Figure 4.1A).  To determine the effect of HCV proteins on 
hMDMs, we stimulated hMDMs with recombinant HCV core or NS3 protein.  
We found that as little as 10 ng/ml of HCV protein induced a dose dependent 
induction of TNF-α in hMDMs (Figure 4.1B).  Despite the high concentrations of 
HCV proteins used in Figure 4.1 the lowest concentrations of protein we used are 
similar to concentrations found in HCV patient serum (209, 245).  It is difficult to 
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confirm the highest levels of HCV proteins circulating or concentrating in the 
human body as most acute infections are not detected or misdiagnosed by 
physicians.  Human MDMs contribute to not only the generation of inflammatory 
responses triggered by pathogen-derived ligands but also to the generation of anti-
inflammatory cytokines, such as IL-10, which can inhibit pathogen-specific T cell 
activation (246).  It is unknown whether TLR2 alone, and/or in combination with 
TLR1 or TLR6, participate in HCV-specific anti-inflammatory production during 
stimulation with HCV core and NS3 protein.  Here we established that hMDMs 
produced IL-10 when stimulated with HCV core or NS3 proteins in a dose 
dependent manner (Figure 4.1C).  Importantly the levels of IL-10 induced with as 
little as 76 ng/ml of HCV proteins were closely comparable with cytokine and 
HCV core protein levels reported in the serum of HCV-infected patients (209, 
245). Beta-galactosidase as stated in the methods was fused with HCV proteins as 
recombinant proteins and was run as a negative control in Figure 9 to assure that 
β-gal fusion to HCV core or HCV NS3 proteins was not contributing or 
interfering with cellular cytokine production.  There was negligible contribution 
by β-gal at a concentration of 5μg/ml to cytokine production in primary 
macrophages therefore we did not run this control in the subsequent figures.  
Since there was a high induction of cytokine from 5ug/ml of HCV protein 
stimulation and there was no induction of cytokine from β-gal at the same 
concentration, we presumed that the activation of macrophages was indeed due to 
HCV protein stimulation as opposed to a general response of adding a high 
concentration of protein onto the cells.   
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Figure 4.1: HCV core and NS3 proteins induce TNF-α and IL-10 production in a 
dose dependent manner in human monocytes and macrophages.  (A) Equal amounts 
of mRNA extracted from normal human monocytes (top gel) and macrophages 
(bottom gel) were transcribed into cDNA and amplified using TLR1-, TLR2-, 
TLR6- and 18S-specific primers in reverse transcription (RT)-PCR. No RT control 
for contaminating products is also shown for each cell type.  One individual out of 
n=3 independent experiments from three subjects with similar results is shown.  
Normal human monocyte-derived macrophages were stimulated with recombinant 
HCV core (open bars) or NS3 (black bars) β-gal fusion proteins for ten hours. 
Culture supernatants were analyzed for TNF-α (B) and IL-10 (C) using specific 
ELISA.  Data are shown as an average±SD ng/ml from three or more experiments. 
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Uncontaminated HCV proteins specifically activate TLR2 in knockout mice 
Before performing siRNA knockdown, we determined that the HCV core 
and NS3 recombinant proteins were TLR2 specific and were void of endotoxin.  
Murine peritoneal macrophages were extracted from wild-type C57BL/6 (Figure 
4.2), TLR2-/- (Figure 4.2B), TLR4 mutant (Figure 4.2C) and TLR4-/- mice 
(Figure 4.2D) and stimulated with TLR2 and TLR4 ligands, HCV core and NS3 
proteins.  IL-6 production from peritoneal macrophages showed that stimulation 
with HCV core and NS3 proteins rendered no response in the TLR2-/- mice as 
opposed to the wild-type, TLR4-/-, or TLR4 mutant mice.  The purified LPS was 
used as a TLR4 specific ligand and the PGN was used as a TLR2 specific ligand.  
Recombinant proteins HCV core and NS3 were fused with β-galactosidase.  β-
galactosidase is commonly used for molecular biology techniques to screen for 
recombinant clones.  To test whether β-gal causes an immune reaction in 
macrophages, we added β-gal provided by Biodesign to macrophages from either 
wild-type, TLR2-/-, TLR4 mutant, or TLR4-/- mice.  There was a negligible 
cytokine response when stimulated with β-gal in any set of macrophages tested.  
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Figure 4.2A-D: Ligand specificity to TLR2 by HCV core and NS3 proteins.  
Peritoneal Macrophages from (A) wild-type C57BL/6, (B) TLR2 -/-, (C) TLR4 
mutant, and (D) TLR4 -/- were stimulated with plain media (no stimulant) as the 
control, pLPS (100 ng/ml), PGN (10 μg/ml), HCV core and NS3 proteins (5 μg/ml), 
and Beta-galactosidase (5 μg/ml).  β-gal was used as a control for non-specific 
cytokine production from the fusion proteins HCV core and NS3.  After twelve 
hours, the culture supernatants were analyzed for IL-6 content using ELISA.  Data 
are shown as an average±SD ng/ml from n=3 independent experiments.   
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TLR2 Specificity in Human Cells 
In human cells over-expressing TLR2 or TLR4 (Figure 4.2E), stimulation 
with TLR2 or TLR4 ligands, HCV core or NS3 proteins showed the same pattern 
of TLR2 specificity.  In HEK/TLR4 cells, PGN, HCV core and NS3 proteins did 
not elicit NF-kB activation as opposed to HEK/TLR2 cells, which showed 
significant activation of NF-kB.  To further investigate the specificity to TLR2 we 
utilized TLR2 blocking antibodies in human monocytes stimulated with the same 
ligands and proteins as in Figure 4.2E, and measured TNF-α production (Figure 
4.2F).  The blocking antibodies resulted in a significant reduction of cytokine 
production compared to the isotype antibody control but did not completely 
inhibit cytokine output.  The remaining cytokine production was most likely due 
to the incomplete blocking by the antibody and not to TLR2 contaminants in the 
HCV core and NS3 proteins as the anti-TLR2 antibody also failed to achieve full 
inhibition of the classical TLR2 ligands (Figure 4.2F).  IL-1β was used as a 
positive cytokine stimulation control in Figure 4.2E to confirm functionality of 
the cells. 
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Figure 4.2E-F: Ligand specificity to TLR2 by HCV core and NS3 proteins. (E) 
HEK293/TLR2 or HEK293/TLR4 cells were stimulated with pLPS (100 ng/ml), 
PGN (10 μg/ml), HCV core and NS3 proteins (5 μg/ml), Beta-galactosidase (5 μg/ml) 
and IL-1β (20 μg/ml).  After twelve hours, the cells were lysed and luciferase NF-kB 
levels were measured.  Data are shown as an average±SD ng/ml from n=3 
independent experiments.  Asterisks (TLR4) and pound (TLR2) symbols represent 
p-values < 0.05 compared to the controls calculated by student’s t-test. (F) Mouse 
peritoneal macrophages were stimulated with LPS, PGN, HCV core and NS3 
proteins, and Beta-galactosidase in the same concentrations as in (E).  Culture 
supernatants were analyzed for TNF-α by ELISA.  Blocking antibodies, isotype and 
TLR2, were added 2 hours before the 16-hour stimulation.  Asterisks indicate p-
values< 0.05 compared to the controls calculated by student’s t-test.  
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Reducing TLR Expression by siRNA 
Based on these findings, we hypothesized that the TLR2 co-receptors, 
TLR1 and/or TLR6, are involved in TLR2-mediated recognition and activation by 
HCV core and NS3 proteins.  HEK 293 cells have endogenous levels of TLR1 
and TLR6 shown in Figure 4.3.  We specifically knocked down TLR2, TLR1 and 
TLR6 receptor-specific mRNA in HEK/TLR2 cells and primary human 
macrophages using siRNA technology to evaluate which TLR2 co-receptor 
participates in TLR2-mediated cell activation by HCV core and NS3 proteins. 
First, to determine the efficiency in the knockdown of the siRNAs, we examined 
the expression of target mRNA over a three day time course after siRNA 
transfection.  For each target TLR, there were two separate sequence siRNAs, 
named sequence (seq)-A and seq-B.  We found a significant reduction (>50%) of 
mRNA in at least one or both of the two separate siRNA sequences for TLR2, 
TLR1 and TLR6 on day 2 after transfection (Figure 4.3A).  To determine whether 
mRNA reduction correlated with loss of protein expression, we examined surface 
protein levels by FACS (Figure 4.3B) and cellular protein levels by Western Blot 
analysis (Figure 4.3C). By day 2, TLR2 surface expression levels dramatically 
decreased with TLR2 seq-a siRNA but not in control siRNA transfected 
HEK/TLR2 cells (Figure 4.3B).  By day 3, there was a >75% decrease in TLR6 
protein expression using TLR6 seq-b siRNA knockdown in HEK/TLR2 cells 
(Figure 4.3C).  Due to the lack of efficient Western Blot- or FACS-suitable 
antibody, TLR1 protein levels could not be determined.  These results suggest that 
the designed siRNAs were specific and functional for knockdown, portrayed by 
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the significant decrease in mRNA and/or protein expression levels of TLR 2, 
TLR1 and TLR6 in HEK/TLR2 cells.   
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Figure 4.3: TLR-specific siRNAs knockdown TLR mRNA and protein expression in 
HEK293/TLR2 cells.  (A) Two different RNAi sequences, Seq-a, Seq-b, were 
constructed to target TLR2, TLR1 and TLR6 and transfected in HEK/TLR2 cells, 
as described in Methods.  The control (Ctrl) represents the baseline expression of 
the corresponding TLR in a negative control siRNA-transfected cells.  A negative 
control siRNA refers to the non-specific scrambled siRNA that does not target any 
gene in the cell for knockdown.  At 24 hrs (day 1) and 48 hrs (day 2) after siRNA 
transfection, the mRNA from HEK/TLR2 cells was extracted and equal amounts of 
mRNA were transcribed into cDNA. The levels of TLR2 (top gel), TLR1 (middle 
gel), and TLR6 (bottom gel) were determined using specific primers and PCR.  18S 
was included as an internal control for all experiments.  PCR products were 
separated on a 1% agarose gel, stained with ethidium bromide and detected upon 
exposure to UV light.  Shown are representative gels from one individual donor out 
of n=3 independent experiments with similar results.  (B) HEK/TLR2 cells were 
transfected with siRNA specific to TLR2 seq-a.  The cells were stained with 
secondary antibody alone (IgG control) or anti-TLR2 antibody followed by 
secondary APC-labeled antibody. The fluorescence was analyzed by flow cytometry. 
The TLR2 expression in cells transfected with the negative control siRNA, as 
described in Methods, was considered as positive control for full TLR2 expression. 
TLR2 expression was determined over a five-day time course; shown are 
representative fluorescence histograms from one experiment analyzed on day 2 
(top), day 3 (middle panel) and day 4 (bottom pane) out of n=4 independent 
experiments with similar results.  (C) HEK/TLR2 cells were transfected with siRNA 
specific to TLR6 seq-b.  Control represents cells transfected with the negative 
control siRNA, as described in Methods.  On day 1 and day 3 after siRNA 
transfection, the cells were lysed, equal amounts of proteins from each experimental 
group were separated in SDS-PAGE, transferred to a membrane and probed with 
specific anti-TLR6 or anti-β-actin antibodies followed by secondary-HRP labeled 
antibodies. The expression of TLR6 (top blot) or β-actin (bottom blot) and the 
densitometric analysis of TLR6 expression adjusted to β-actin from one experiment 
out of n=3 independent experiments with error bars representing + SD density units 
with similar results is shown.  
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Specific siRNA knockdown significantly reduces function in HEK/TLR2 cells 
To evaluate if the receptor knockdown correlated with reduced receptor 
function, we stimulated siRNA-transfected cells with TLR specific ligands, 
including the TLR2 ligand, PGN, TLR2/1 ligand, Pam3CSK4, and TLR2/6 
ligand, Pam2CSK4, and measured cell activation by means of cytokine 
production.  TLR-specific siRNAs knocked down IL-8 cytokine production in 
HEK/TLR2 cells when compared to control siRNAs (Figure 4.4).  TLR2 RNAi 
transfection resulted in a significant loss of function indicated by a decrease in IL-
8 production (50-75%) compared to control siRNA after stimulation with all three 
TLR2 ligands: PGN (TLR2/6), Pam2CSK4 (TLR2/6), and Pam3CSK4 (TLR2/1) 
(Figure 4.4A).  TLR1 silencing resulted in significant IL-8 reduction (~57%) after 
stimulation with TLR2/1 ligand, Pam3CSK4, and not with the TLR2/6 ligand, 
Pam2CSK4, indicating specific TLR1 silencing (Figure 4.4B).  TLR6 silencing 
also showed specificity in functional knockdown as significant reduction occurred 
with Pam2CSK4 (TLR2/6) and not with Pam3CSK4 (TLR2/1) ligand (Figure 
4.4C).  These results implied that knockdown of mRNA transcripts and protein 
expression by RNA interference method correlates with a significant reduction in 
TLR receptor function and inhibition of ligand-stimulated cytokine production. 
We used IL-1β as a stimulation control, which was unaffected by transfection of 
any of the siRNAs (Figure 4.4D) since IL-1β induces cell activation via IL-1β 
receptor and not via TLRs.  We also tried a variety of ways to increase siRNA 
knockdown, from increasing siRNA concentration to increasing and varying 
transfection reagents (data not shown).  No other techniques yielded a higher 
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knockdown and in some cases such as increasing transfection reagent or high 
siRNA concentrations, caused cell death.  We also attempted to produce a double 
knockdown (TLR1/TLR6) siRNA to confirm that only these co-receptors were 
involved in TLR2 activation by HCV proteins.  Double knockdowns also yielded 
cell death or little knockdown of one but not the other.   
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Figure 4.4: Specific siRNAs for TLR2, TLR1 and TLR6 affect functional outcome of 
these receptors in HEK/TLR2 cells.  HEK/TLR2 cells were transfected with siRNAs 
specific for TLR2 (A), TLR1 (B) and TLR6 (C) receptors.  Control represents cells 
transfected with a negative control siRNA, as described in Methods.  On day 3 after 
siRNA transfection the cells were stimulated for ten hours with PGN (TLR2/TLR6 
ligand) at 5 μg/ml, Pam3CSK4 (TLR2/TLR1 ligand) at 50 ng/ml, Pam2CSK4 
(TLR2/TLR6 ligand) at 5 μg/ml or recombinant IL-1β at 50 ng/ml (D) and the IL-8 
production in culture supernatants was ascertained using a specific ELISA. Data 
are shown as an average±SD ng/ml from n=3 independent experiments. P-values 
were compared to the controls and calculated by student’s t-test.  
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Identifying the TLR2 Co-receptor Participating in HCV Protein Recognition 
After we confirmed the specificity of siRNAs to TLR2, TLR1 and TLR6, 
we intended to establish which TLR2 co-receptor participates in recognition of 
HCV proteins, core and NS3.  TLR2 ligand controls were tested on siRNA 
knockdowns along with the HCV proteins (data not shown).  In HEK/TLR2 cells, 
knockdown of all three targeted siRNAs, TLR2 (Figure 4.5A), TLR1 (Figure 
4.5B) and TLR6 (Figure 4.5C) individually, resulted in significant inhibition of 
HCV core- (p<.009, p<.02, p<.005, respectively) and NS3- (p<.003, p<.03 
p<.002, respectively) induced IL-8 production compared to a control siRNA 
(Figure 4.5A, B, C).  Figure 12C tested a higher concentration of HCV proteins to 
confirm that knockdown was not affected by concentration of stimulant.  Both 
TLR2 and TLR1 were also tested at 10 μg/ml with HCV proteins but yielded the 
same results as in Figure 4.5 (data not shown).  Knockdown of at least 50% was 
sufficient enough to cause a loss of function of the receptor when stimulated with 
HCV proteins.  The absence of TLR2 or either of its co-receptors, TLR1 or TLR6, 
greatly diminished cellular activation by HCV NS3 and core proteins.  These 
results suggest that both TLR1 and TLR6 participate in TLR2 activation by HCV 
NS3 and core.   
83 
 
 
Figure 4.5: TLR2, TLR1 and TLR6 participate in recognition of HCV core and NS3 
proteins in HEK/TLR2 cells.  HEK/TLR2 cells were transfected with siRNA specific 
for TLR2 (top panel), TLR1 (middle panel) and TLR6 (bottom panel). Control 
represents cells transfected with a negative control siRNA, as described in Methods.  
Three days after siRNA transfection, the cells were stimulated for ten hours with 
HCV core and NS3 proteins at 5 μg/ml for (A and B) 10μg/ml for (C) and the IL-8 
production in culture supernatants was ascertained using IL-8 specific ELISA.  
Data are shown as an average±SD ng/ml from n=3 independent experiments. P-
values were compared to the controls and calculated by student’s t-test.  
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Both TLR2 co-receptors participate in HCV protein activation in hMDMs 
To assess the involvement of TLR1 or TLR6 in HCV protein stimulation 
in macrophages, we stimulated TLR-specific siRNA-transfected hMDMs with 
HCV proteins.  There was a significant reduction in TNF-α (Figure 4.6A) and IL-
6 (Figure 4.6B) production in all three TLR-specific siRNA-transfected 
macrophages stimulated with Pam2SCK4 (TLR2/TLR6), Pam3CSK4 
(TLR2/TLR1) or PGN (TLR2/TLR6), suggesting a loss of function.  Upon sole 
transfection of siRNA (medium control) there were no cytokines detected (Figure 
4.6A, B).  Silencing of TLR2, TLR1 or TLR6 did not affect TLR4-induced 
(pLPS) IL-6 or TNF-α production in hMDMs, confirming the lack of cross 
reactivity.  More important, both TLR1 and TLR6 silencing caused reduced levels 
of inflammatory cytokines, TNF-α (Figure 4.6A)  and IL-6 (Figure 4.6B), when 
stimulated with HCV core or NS3 proteins. TLR2, TLR1 and TLR6 knockdowns 
in hMDM cells followed the same pattern as in the HEK/TLR2 cells (Figure 4.4), 
supporting the hypothesis that both TLR1 and TLR6 are involved in conjunction 
with TLR2, in cellular activation by HCV core and NS3.  In Figure 4.6, p-values 
were insignificant where there were no symbols.   
To evaluate whether the anti-inflammatory response from HCV protein 
stimulation in macrophages is dependent on TLR2, TLR1 or TLR6, we measured 
IL-10 levels after TLR-specific knockdown in hMDMs stimulated with HCV core 
or NS3 proteins.  There was a significant attenuation in IL-10 induction in TLR2 
siRNA-transfected hMDMs after stimulation with core or NS3 proteins, 
suggesting that TLR2 was important for IL-10 production (Figure 4.6C). TLR1 
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and TLR6 siRNA attenuated IL-10 induction by HCV core and NS3 proteins in 
macrophages, but only TLR1 knockdown resulted in significant inhibition of 
NS3-induced IL-10 (Figure 4.6C).  These results suggest that TLR2 is involved in 
IL-10 induction by HCV core and NS3 stimulation. 
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Figure 4.6: Targeting of TLR2, TLR1 and TLR6 with specific siRNA conditions 
reduced cytokine production in human monocyte-derived macrophages.  Human 
monocyte-derived macrophages were transfected with siRNA specific for TLR2, 
TLR1, TLR6 or non-specific scrambled negative control (Control).  Columns 
marked Media were unstimulated cells transfected with one of the four siRNAs.  On 
day 3 after siRNA transfection, the cells were stimulated with Pam3CSK4 
(TLR2/TLR1 ligand) at 50 ng/ml, Pam2CSK4 (TLR2/TLR6 ligand) at 5 μg/ml, PGN 
(TLR2/TLR6 ligand) at 10 μg/ml, phenol extraction-purified LPS (TLR4 ligand) at 
100ng/ml or HCV core and HCV NS3 proteins at 5 μg/ml, as indicated. TNF-α (A), 
IL-6 (B) and IL-10 (C) were measured in culture supernatants using specific ELISA.  
Data are shown as an average±SD ng/ml from n=5 independent experiments. The 
stars indicated the p<0.05 calculated using student’s T-test in siRNA-transfected 
samples compared to corresponding scrambled siRNA controls. 
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Investigating effects of HCV in complete TLR2, TLR1, or TLR6 knockout 
mice shows a significant TLR2/6 dependence for HCV activation 
Our method of knockdown by siRNA transfection was neither complete 
nor stable and left residual cytokine production during stimulation.  Thus, we 
employed peritoneal macrophages isolated from TLR-specific knockout mice as 
an alternate approach to determine the roles of TLR2, TLR1, or TLR6 receptors 
in HCV protein-induced stimulation.  In accordance with previous findings (79), 
the absence of TLR2 prevented TNF-α induction by HCV core, NS3 or TLR2 
ligand stimulation (Figure 4.7A).  Macrophages from TLR1-/- mice showed a 
slight decrease yet not significant in TNF-α production when stimulated by 
recombinant HCV core or NS3 proteins (Figure 4.7B).  Contrary to the TLR1-/-, 
macrophages from TLR6-/- mice had a significantly attenuated TNF-α production 
upon HCV core or NS3 protein stimulation (Figure 4.7C), compared to wild type 
animals.  These results imply that in mouse peritoneal macrophages TLR2 and 
TLR6, but possibly not TLR1, are substantially involved in HCV core or NS3 
protein-induced activation.  
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Figure 4.7: HCV core and NS3 protein employ TLR2 and TLR6 to activate mouse 
peritoneal macrophages.  The peritoneal macrophages of TLR2 (A), TLR1 (B), 
TLR6 (C) knockout mice or wild-type mice were stimulated with Pam3CSK4 (Pm3, 
TLR2/TLR1 ligand) at 200 ng/ml, Pam2CSK4 (Pm2, TLR2/TLR6 ligand) at 10 
µg/ml, or phenol extraction-purified LPS (TLR4 ligand) at 200 ng/ml.  HCV core 
and HCV NS3 proteins were employed at serial dilution concentrations between 10-
0.1 µg/ml, as indicated. After ten hours, the culture supernatants were analyzed for 
TNF-α content using ELISA.  Data are shown as an average±SD ng/ml from n=3 
independent experiments.  The stars indicated the p<0.05 calculated using student’s 
T-test in cells with siRNA-transfected samples compared to corresponding 
stimulation in wild-type cells.  
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Chapter Summary 
TLR2 is a diverse innate immune receptor involved in HCV protein 
recognition and activation.  Effects of innate immune activation by HCV proteins, 
core and NS3 identified the specific involvement of TLR2 in mononuclear cells.  
TLR2 activation occurs by heterodimerization with either TLR1 or TLR6 (202).  
We wanted to further identify which heterodimer was responsible for 
mononuclear cell activation by HCV proteins.  We established comparable 
expression of TLR 1, TLR2, and TLR6 in both monocytes and macrophages and 
showed that both HCV core and NS3 stimulate human monocytes derived 
macrophage production of TNF-α or IL-10 in a dose dependent manner.  We also 
confirmed HCV protein specificity to TLR2 using TLR knockout mice and HCV 
protein purity, devoid of contaminants that might stimulate TLR2.   
To determine which TLR2 heterodimer was responsible cellular activation 
from HCV proteins, we utilized siRNA knockdown technology in HEK/TLR2 
cells and primary human macrophages.  TLR2, TLR1 and TLR6 knockdowns 
were observed from both RNA and protein levels and a significant yet not 
complete reduction of function was perceived in HEK/TLR2 cells when 
stimulated with various TLR2 ligands.  Knockdowns were specific to the TLR 
gene and did not affect functionality of other TLR2 heterodimers or the IL-1β 
receptor.  Administration of HCV proteins showed participation of both TLR2/1 
and TLR2/6 heterodimers as there was a significant loss of function in all three 
separate knockdowns upon stimulation.   
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RNAi knockdown experiments in primary macrophages showed a TLR1, 
TLR2, and TLR6 requirement for complete production of IL-6 when stimulated 
with HCV proteins.  Yet for production of either TNF-α or IL-10 there was 
variable use of TLR2 and its heterodimers in primary macrophages.  Since siRNA 
technology was not a complete knockout of TLRs, we wanted to confirm our 
findings in TLR specific knockout mice.  TLR6 showed significant but not full 
reduction of function with both HCV proteins compared to TLR1 which was not 
significant with either protein.  Therefore, in mice, TLR2/6 seems to be required 
for full HCV protein-mediated cellular activation.   
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CHAPTER V 
Impaired expression and function of Toll-like receptor 7 from Hepatitis C 
Virus infection in human hepatoma cells 
 Expression of Toll-like receptors is not restricted to immune cells and recent 
studies suggested that human hepatocytes express mRNA for all TLRs (247).  
TLR7 agonist, Isatoribine, reduced HCV infection in patients after one week of 
treatment.  Another group generated a more potent specific TLR7 agonist which 
reduced HCV replication and protein in HCV replicating cell lines.  Based on 
these previous reports connecting TLR7 with the reduction of HCV infection 
(197, 198), we postulated that TLR7 may play a role in anti-HCV immunity.  
Specifically, we analyzed whether HCV interferes with TLR7 expression and/or 
functions in a disruptive manner. 
Active HCV replication in HCV cell lines 
To address our hypothesis, we used Huh7 and Huh7.5 hepatoma control 
cell lines and HCV-replicating stable cell lines FL, containing the full length 
HCV genome transfected into Huh7.5, BB7, containing the subgenomic HCV 
genome transfected into Huh7, and JFH-1, containing the infectious full length 
HCV genome transfected into Huh7.5 (Figure 5.1A).  HCV FL and BB7 have an 
antibiotic selectable marker (Neomycin) before the core gene for FL and before 
EMCV for BB7.  JFH-1 does not have a selectable marker as it is the only 
infectious HCV genome readily electroporated into cells and contains only the 
HCV RNA sequence.  The genome for JFH-1 was not contained within a plasmid 
that would contain the Neomycin gene.  HCV NS5A protein expression was 
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confirmed by Western analysis for all HCV-expressing cell lines (Figure 5.1B) 
and by immunofluorescence detection of HCV core protein, expressed in FL and 
JFH-1 but not in BB7 (Figure 5.1C).  
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Figure 5.1:  Hepatoma cells transfected with various HCV genomes show actively 
replicating HCV.  (A) Protein map encoded by HCV genome in HCV replicating cell 
lines JFH-1, full length HCV genotype 2a, FL, full length HCV genotype 1a, and 
BB7, subgenomic HCV genotype 1b. Neo refers to neomycin selectable marker.  (B)  
HCV replicating cells and hepatoma control whole cell extracts (5 μg) 
immunoblotted against antibodies for HCV NS5A or B-Actin.  B-Actin was used as 
a loading control.  Data shown is one representative experiment of n=3 independent 
experiments with similar results.  (C) Immunofluorescence of fixed hepatoma and 
HCV replicating cells on slide.  Nucleus stained in blue (DAPI) HCV core protein 
stained in red. Data shown is one representative experiment of n=4 independent 
experiments with similar results. 
Neo 
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Low TLR7 expression measured in HCV replicating cells. 
We identified detectable TLR7 RNA (Figure 5.2A) and protein levels 
(Figure 5.2B) in control Huh7 and Huh7.5 cells.  There was a significant decrease 
of TLR7 RNA (Figure 5.2A) and protein (Figure 5.2B) in all HCV cell lines.  The 
TLR7 high population in the Huh7 cells could be artifact staining as this 
population was not consistent with other staining of TLR7 in Huh7 cells.  It most 
likely results from improper wash techniques after temporary permeabilization of 
the cells.  These data suggest that TLR7 levels are impaired in the presence of 
HCV in vitro. To determine if low levels of TLR7 correlate with the presence of 
HCV infection in patients, we analyzed the levels of TLR7 RNA in the HCV 
infected and control livers (Figure 5.2C).  Liver tissue samples were from HCV 
chronically infected individuals with high viral titers measured by PCR (data not 
shown).  Expression of TLR7 RNA was significantly reduced in livers of patients 
with chronic HCV infection compared to healthy, HCV-naive controls.  These 
results suggest that the presence of HCV correlated with reduced levels of TLR7. 
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Figure 5.2: Hepatoma cells actively replicating HCV show reduced TLR7 mRNA 
and protein.  (A) RNA extracts of HCV replicating and hepatoma control cells used 
to amplify TLR7 mRNA by quantitative real time PCR normalized to GAPDH 
mRNA.  Data are shown as n=3 independent experiments Data was quantitated 
using the 2-ΔΔCt method.  Data are shown as an average + SD with p-values 
calculated using student’s t-test.  (B) Hepatoma and HCV replicating cells fixed, 
permeabilized and stained for TLR7 receptor using flow cytometry.  Negative 
controls included unstained samples (not shown) and secondary antibody only 
stained samples (shown as dotted grey line) Data is representative of one of n=3 
independent experiments with similar results (C) RNA extracts of HCV patient liver 
samples and control liver samples obtained as stated in methods.  HCV average 
indicates the average TLR7 mRNA of the 6 HCV patient samples. Three healthy 
control liver samples were tested and averaged.  Data are shown as an average + SD 
with p-values calculated using student’s t-test. 
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HCV clearance by IFNα re-establishes TLR7 expression  
 Reduced TLR7 expression in HCV replicating hepatoma cells and in the livers 
of HCV infected patient indicated a novel phenotype possibly caused by HCV 
infection.  Thus, we hypothesized that the reduced TLR7 expression was due to 
HCV replication.  To test whether there is a direct effect of HCV infection on 
TLR7 levels, we reduced HCV replication by either administration of IFNα 
treatment, cultured stable HCV-expressing cell lines in selection antibiotic-
depleted media, or self-restriction of viral replication through high passage 
number of JFH-1 cells, followed by the analysis of TLR7 levels.  We analyzed 
mRNA content through quantitative real-time PCR calculated using a relative 
standard curve method.  HCV mRNA was performed with the more precise and 
expensive Taqman probes while TLR7 mRNA was performed with the less 
precise but still quantitative Sybr green protocol.  Sybr green QRT-PCR was used 
for economical reasons.  Both HCV and TLR7 were normalized against GAPDH. 
Treatment of HCV replicating cells with IFNα over a forty-eight hour time 
course led to time-dependent reduction of HCV replication in all three HCV cell 
models including FL, BB7 and JFH-1 (Figure 5.3A).  In contrast to significant 
decreasing HCV levels (Figure 5.3A), TLR7 RNA significantly increased upon 
IFNα treatment in all three HCV replicating cells (Figure 5.3B).  TLR7 levels 
doubled in control cells treated with IFN-α after 2 hours (Figure 5.3B).  TLR7 
levels in control cells increased slightly or decreased after 2 hours.  Even though 
TLR7 RNA levels in control cells did increase upon IFN-α administration, there 
was a significant (p<0.05) TLR7 RNA increase in HCV replicating cells 
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compared to the control cells after the 2 hour time point.  The only significant 
TLR7 RNA increase in control cells was at the 2 hour time point when compared 
with the subgenomic cell line, BB7, which did not increase TLR7 levels above 
baseline.  These results suggest that IFN-α does have some control over TLR7 
RNA levels.  Curing HCV replicating cells with IFNα directly correlated with 
conventional levels of TLR7. 
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Figure 5.3: IFNα curing of HCV replication increases TLR7 mRNA expression.  (A) 
HCV mRNA was amplified by Taqman QRT-PCR normalized to GAPDH mRNA 
levels and (B) TLR7 mRNA amplified by Sybr Green QRT-PCR in HCV replicating 
cells, FL, JFH-1, and BB7 and in control cells, Huh7 and Huh7.5.  1ng/ml of IFNα 
was administered to cells for a 48 hour time course and samples were taken at 
indicated intervals.  Data was quantitated using the 2-ΔΔCt method.  Data are shown 
as an average + SD of n=3 independent experiments. P-values were calculated by 
student’s t-test and compared to the controls.   
R
el
at
iv
e 
qu
an
tit
y 
of
 T
LR
7 
R
N
A
 
101 
 
Natural ‘curing’ due to depletion of selective media in stable HCV 
replicating cell lines confirms TLR7 protein restoration 
To verify these findings we followed up these results by culturing FL and 
BB7 HCV replicating cells without selection media, G418.  After seven days, we 
observed similar restoration of TLR7 RNA (Figure 5.4A) upon diminishing HCV 
replication.  TLR7 expression was not affected by cell growth phases over the 
seven day time course in control cells.  Effects of G418 on TLR7 expression was 
not properly tested and would need to be performed to confirm that these effects 
are not from addition of G418.  G418 was added to control hepatoma cells for a 
seven day period (data not shown).  48 hours with G418 was enough to cause cell 
death in the control cells.  The proper experiment would be to transfect hepatoma 
control cells with an empty vector containing the G418 resistance, add G418 and 
measure TLR7 expression levels over time.  Experiments with the IFNα curing 
did not show any difference in TLR7 protein restoration after two days (data not 
shown).  Therefore we investigated protein levels during a longer time course in 
HCV replicating cells without selection media.  Protein levels returned to non-
HCV control cells after four days (Figure 5.4B) upon diminished HCV 
expression.  These results confirm the direct effect HCV replication has on 
diminished TLR7 expression in both FL and BB7.   
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Figure 5.4: Reduction of HCV replication by exclusion of selective media, G418, in 
HCV stable cell lines increases TLR7 mRNA and protein expression.  (A) RNA was 
extracted from HCV stable cell lines FL and BB7 and amplified by Taqman QRT-
PCR normalized to GAPDH mRNA levels. TLR7 mRNA was amplified by Sybr 
Green QRT-PCR in HCV stable cell lines FL and BB7.  Stable TLR7 expression in 
hepatoma control cells.  RNA was extracted from hepatoma control cells and used to 
amplify TLR7 mRNA by Sybr Green QRT-PCR normalized with GAPDH.  Cells 
were maintained in G418 deficient media and were used as a TLR7 mRNA time 
course control.  Data was quantitated using the 2-ΔΔCt method.  Data are shown as an 
average + SD of n=4 independent experiments.  P-values were calculated by 
student’s t-test and compared to the controls.  (B) Cell samples stained with TLR7 
antibody representing TLR7 protein levels using flow cytometry. Cells stained with 
IgG controls are shown by (—•—) in the left panel and red in the right panel.  
Unstained controls are shown in blue in the right panel and solid grey in the left 
panel.  HCV replicating cells were passed and maintained in G418 deficient media 
on day 0 and RNA and protein samples were taken on the indicated days over a 
period of one week.  Data is representative of one of n=4 independent experiments 
with similar results.    
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To corroborate these results in JFH-1 cells, we examined TLR7 protein 
levels in parallel with HCV expression over a series of passages.  JFH-1 
replication was depleted after fourteen serial passages while TLR7 protein levels 
were restored (Figure 5.5).  These data show a direct correlation between active 
HCV replication and decreased TLR7 expression.   
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Figure 5.5: Diminished HCV infection from serial passages of JFH-1 cells increases 
TLR7 protein expression.  RNA extracts were taken from JFH-1 cells from the 
indicated passage number and HCV mRNA was amplified using Taqman QRT-
PCR normalized with GAPDH and displayed on the right side Y-axis, black line.  
TLR7 protein levels were quantified by flow cytometry from cells fixed, 
permeabilized and stained against TLR7 from the indicated passage number 
displayed on the left side Y-axis, gray line.  JFH-1 cells were passed every three to 
four days with the first passage performed after electroporated cell recovery 
described in the Materials and Methods. Data was quantitated using the 2-ΔΔCt 
method.  Data is representative of one independent experiment with n=3 replicate 
wells.   
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RNA instability is a mechanism for HCV modulation of TLR7 
 Deficient production of RNA coding for a gene, which can lead to impaired 
protein expression, is often caused by modifications at the level of gene 
transcription (248). More importantly, some viruses manipulate host mRNA 
stability to achieve delayed and/or impaired immune responses, thus leading to 
viral persistence (249, 250). Considering that our results in HCV replicating cells 
showed decreased TLR7 RNA due to HCV replication, and recent report of HCV 
NS5A protein interference with the TLR7-mediated signaling pathway resulting 
in impaired cytokine production (236), we predicted that HCV may affect the 
stability of TLR7 mRNA. To investigate this hypothesis, we utilized actinomycin 
D, an inhibitor of mRNA transcription achieved by binding the DNA at the 
transcription initiation complex and thus preventing elongation by RNA 
polymerase (251), and quantified the TLR7 mRNA half life levels using real time 
PCR over a twenty-four hour time course.  TLR7 quantification was normalized 
to β-actin instead of GAPDH.  β-actin mRNA is more stable than GAPDH and 
TLR7 which makes this gene more appropriate to use for normalization than one 
that is less stable.  The 24 hour time point was not used to calculate the half life as 
it yielded slightly reduced viability.  There were values detected up to 8 hours but 
at the 24 hour time point there were a few undetectable values which did not 
affect half life values since I did not include the 24 hour time point in this 
calculation.  If any experiment had one abnormal CT value (no value at all or 
extremely high) detected in the PCR, I would discard the whole experiment.  The 
half-life of TLR7 mRNA using actinomycin D was significantly shorter in HCV-
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replicating cells compared to controls (Figure 5.6A, Figure 5.6B). A similar 
pattern of shortened half-life of TLR7 mRNA instability in HCV replicating cells 
was observed using alpha-amanitin, another inhibitor of mRNA transcription 
which interacts with the bridge helix in RNA polymerase II, allowing it to disrupt 
the translocation of RNA required to vacate the area for the next round of RNA 
synthesis (252) (Figure 5.6C, Figure 5.6D).  The larger standard deviation in the 
Huh7 cells using alpha-amanitin caused a p-value greater than 0.05.  Even though 
these results did not fall under the strict p-value limit for significance, the trend of 
reduced stability of TLR7 mRNA in HCV replicating cells compared to controls 
was followed.  These results suggest mRNA instability as one mechanism that 
HCV utilizes to circumvent induction of TLR7.  
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Figure 5.6: RNA polymerase inhibitors reveal TLR7 mRNA shortened half-life in 
HCV replicating cells compared to control cells.  (A and B) Cells were treated with 
RNA polymerase inhibitor actinomycin D (2 μg/ml) or (C and D) alpha amanitin (10 
μg/ml) up to 24 hours.  (A. and C.) are shown as semi-log representation up to 9 
hours with the respective regression lines for each cell type.  RNA extracts were 
taken at the indicated time points and TLR7 mRNA was quantitated by QRT-PCR 
normalized with β-actin.  Data was quantitated using the 2-ΔΔCt method.  Data are 
shown as an average + SD of n=3 independent experiments.  (B and D) Half life was 
calculated using the first order rate equation from the slope of the natural log of 
points shown in (A and C).  Data are shown as an average +SD of n=3 independent 
experiments.  P-values were calculated by student’s t-test and compared to the 
controls.   
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RNA instability is specific to TLR7 in HCV replicating cells 
To verify that this mechanism is specific to TLR7 and not a global effect 
of HCV replication, we investigated the half-life of TLR5 in HCV replicating 
cells.  TLR5 and TLR7 baseline levels in hepatoma cells are very similar unlike 
TLR4 levels, which we also investigated but half-life of TLR4 mRNA was more 
erratic (data not shown).  Reduction in mRNA stability was specific to TLR7, as 
the half-life of TLR5 mRNA, a TLR which does not recognize viruses or viral-
derived products (253), was similar in control cells and HCV replicating cells 
(Figure 5.7).  There were no significant changes to TLR5 half-life between HCV 
replicating cells and non-HCV control cells in either actinomycin D (Huh7.5/FL - 
p<0.52, Huh7/BB7 - p<0.92; Figure 5.7B), or alpha amanitin (Huh7.5/FL – 
p<0.67, Huh7/BB7 – p<0.72; Figure 5.7D).  These results establish specificity to 
decreased TLR7 mRNA stability in HCV replicating cells.   
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Figure 5.7: HCV replication does not affect TLR5 half-life. Cells were treated with 
RNA polymerase inhibitors either actinomycin D (A and B) or alpha-amanitin (C 
and D) for 24 hours.  (A. and C.) are shown as semi-log representation up to 9 hours 
with the respective regression lines for each cell type.  RNA extracts were taken at 
the specified time points and were used to quantify TLR5 mRNA by QRT-PCR 
normalized with β-actin.  Data was quantitated using the 2-ΔΔCt method.  Data are 
shown as an average + SD of n=3 independent experiments. (B and D) Half life was 
calculated using the first order rate equation from the slope of the natural log of 
points shown in (A and C).  Data are shown as an average +SE of n=3 independent 
experiments.   
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Furthermore, actinomycin D and alpha-amanitin, inhibitors used in the 
message stability experiments had little effect on HCV replication (Figure 5.8).  
β-actin was used for normalization of HCV levels and β-actin did not decrease 
after 24 hours with inhibitors.  HCV replication with inhibitors neither increased 
nor decreased dramatically after 8 hours.  Up to 24 hours the HCV replication 
increased in FL and BB7 despite treatment with RNA polymerase inhibitors 
unlike a third inhibitor that did reduce HCV replication (data not shown).  These 
results indicate that HCV replication can decrease TLR7 expression by way of 
TLR7 mRNA instability.   
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Figure 5.8: HCV replication is not affected by RNA polymerase inhibitors.  Cells 
were treated with RNA polymerase inhibitors either actinomycin D or alpha-
amanitin for 24 hours.  RNA extracts were taken at the specified time points and 
were used to quantify HCV replication by QRT-PCR normalized with β-actin.    
Data was quantitated using the 2-ΔΔCt method.  Data are shown as an average + SD 
of n=3 independent experiments.   
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IRF7 activation is stunted in HCV replicating cells when stimulated with 
TLR7 agonist 
Our results so far showed a correlation between HCV replication and 
impaired TLR7 expression.  Others have reported an increased baseline 
expression of Type 1 IFN-inducible genes in HCV-infected patients (247, 254), 
but no significant increase in IFN-dependent genes, ISG-15 and OAS, in HCV 
infected patients when given isatoribine, a TLR7 agonist (197).  These data 
together prompted us to explore the effect of HCV replication on the TLR7-
mediated Type 1 IFN signaling pathway. IRF7 is vital to TLR7-induced type I 
IFN production (255). Using ImageStream technology, we analyzed the activation 
of IRF7 by investigating IRF7 nuclear translocation in control and HCV 
replicating hepatoma cells. Unstimulated control cells show IRF7 localized in the 
cytoplasm separate from the nuclear compartment (Figure 5.9A) while stimulated 
cells present IRF7 co-localized with the nucleus (Figure 5.9B).  The majority of 
control cells showed minimal IRF7 nuclear translocation and baseline activation 
of IRF7 (Figure 5.9C). In contrast to control cells, unstimulated HCV replicating 
cells, FL (p<0.01) and BB7 (p<0.04), had a significantly higher baseline 
activation of IRF7 (Figure 5.9C).  Upon stimulation with the TLR7 ligand, control 
cells, Huh7 (p<0.01) and Huh7.5 (p<0.04), show a significant up regulation of 
IRF7 activation.  HCV replicating cells did show an increase in IRF7 nuclear 
translocation, yet it was not significant in either FL or BB7 (p>0.05) (Figure 
5.9D). The observation that stimulation of HCV replicating cells with R837 
triggered only minimal activation of IRF7 compared to the existing high baseline 
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activation was in agreement with low expression of TLR7 (Figure 5.1).  These 
results indicate that the presence of HCV modulates the baseline expression of 
IRF7; however the TLR7-induced activation of HCV replicating cells is impaired.  
Due to the existing upregulated IRF7 nuclear translocation at baseline in HCV 
replicating cells, we can not rule out the possibility that statistically significant 
increases in IRF7 nuclear translocation may not be possible.   
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Figure 5.9: Type 1 IFN-mediated pathway via IRF7 nuclear translocation is elevated 
in HCV replicating cells yet less responsive by TLR7 stimulation compared to 
control cells.  Fluorescent images of unstimulated (A) or stimulated with TLR7 
ligand, R837, (B) hepatoma control cells using ImageStream technology.  Control 
cells were fixed, permeabilized and stained with IRF7, green, and nucleus, red.  
Cells were analyzed by the ImageStream system that individually excites 
fluorescently stained cells with a 488 nm laser and a brightfield light source while 
collecting cell images equivalent to 40-60X magnification and fluorescent intensity 
data through a custom CCD camera.  The brightfield is shown to the left and co-
localization is shown by a merged image of the IRF7 and nuclear images shown to 
the right.  (C) Unstimulated control and HCV replicating cells were fixed, 
permeabilized and stained for IRF7 and nucleus then analyzed on the ImageStream 
system.  Percent of IRF7 nuclear translocation was calculated from the IDEAS 
software using data collected from 10,000 events in each sample.  (D) Percent of 
IRF7 nuclear translocation after TLR7 ligand, R837 10μg/ml, stimulation up to 4 
hours.  Data are shown as an average + SD of n=3 independent experiments.   
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Chapter Summary 
HCV proteins disrupt innate immune receptors that generate Type 1 IFNs.  
TLR7 is a viral recognition receptor that warns the cell of single stranded RNA 
viruses by releasing Type 1 IFNs, particularly IFNα.  Stimulating TLR7 in HCV 
patients or HCV replicating cell lines has proven detrimental for viral survival.  
The major caveat to this treatment is the immense quantities of TLR7 agonists 
necessary for potency.  Therefore, we investigated whether TLR7 was a target of 
HCV infection in hepatocytes.  First, we confirmed HCV replication in all three 
HCV replicating cell lines by NS5A and core protein presence.  TLR7 RNA and 
protein levels in HCV cell lines and HCV infected patient liver samples showed a 
significant reduction compared to healthy controls.  The direct link to HCV with 
this phenotype was verified by exploring TLR7 levels after HCV was reduced.  
Curing HCV replicating cells with IFNα restored TLR7 RNA levels after 24 
hours, but did not show protein restoration after 48 hours.  To confirm these 
results and show protein restoration, we grew HCV replicating cells requiring 
selection media for HCV replication, devoid of selection antibiotics.  After 7 
days, the HCV replication dramatically decreased while the TLR7 levels were re-
established.  The TLR7 protein levels also returned to normal but only after 4 
days, which accounts for the lack of TLR7 protein restoration during IFNα curing.  
JFH-1 cells do not sustain HCV replication indefinitely and perform a self-curing, 
therefore corroborated our previous results by showing a reduction in HCV 
replication over time in JFH-1 cells proved to restore TLR7 protein levels.   
122 
 
 One of the mechanisms by which HCV reduces TLR7 expression is reducing 
TLR7 RNA stability.  The half-life of TLR7 in HCV replicating cells was shorter 
than control cells when utilizing two different RNA polymerase inhibitors.  
Stability of other TLRs such as TLR5 was not affected in HCV replicating cells 
and thus proves specificity to TLR7.  RNA polymerase inhibitors did not cause 
much change in HCV replication.  We further investigated the downstream IFNα-
mediated pathway which in TLR7 is mainly directed by IRF7 nuclear 
translocation.  Using ImageStream technology we quantitated IRF7 nuclear 
translocation in stimulated and unstimulated HCV and control hepatoma cell 
lines.  HCV replicating cell lines have an already high baseline IRF7 activation 
that is not significantly amplified with further TLR7 stimulation compared to 
control cells.  These results suggest further downstream consequences to 
diminishing TLR7 expression. 
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CHAPTER VI 
DISCUSSION 
The aim of this dissertation was to establish the influence Hepatitis C virus 
has on Toll-like receptors in hepatocytes and macrophages.  We hypothesized that 
HCV modulates TLRs to escape the immune system and ultimately establish 
chronic infection.  We explored this aim in three parts: first establishing the TLR 
profile in hepatocytes to identify two potential targets of HCV, testing their 
function and determining whether hepatocytes like many other cell types can be 
activated by HCV; next, we continued to determine the identity and extent of 
functional efficiency of specific TLR2 heterodimers responsible for macrophage 
activation by HCV; finally, we sought to investigate how HCV affects TLR7 
expression.  Mechanisms for HCV chronic infection and immune modulation are 
unknown and therefore exploring the unique phenotypes caused by infection 
provides insight and possibilities for novel therapies in the future.   
We did not use any correction method such as Bonferroni in our statistical 
analysis.  We used the student’s t-test for analysis with the cell culture lines 
because we always compared two paired data sets from each other.  The student’s 
t-test is used for analysis of two data sets that are normally distributed with 
similar variances.  Using a Bonferroni correction would yield strict parameters 
with smaller p-values that would only result in a few changes to significance on a 
few figures.   
Hepatocytes involved in inflammatory response to HCV 
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Previous literature surrounding HCV research established immune 
activation in innate immune cells (79, 208).  While there has been much research 
in hepatocytes regarding HCV immune evasion from activation of IFN-mediated 
pathways (105-107, 171, 172) hepatocytes were not thought to contribute to the 
immune mediated inflammation caused by HCV.  Despite this notion, hepatocytes 
were characterized as containing functional TLRs yet it was unknown whether 
these cells greatly contributed to inflammation due to HCV infection (256).  We 
examined the possibility of innate immune activation in hepatocytes by HCV 
proteins which could contribute to the inflammatory response.  We also confirmed 
the expression and function of specific TLRs that might be involved in HCV 
modulation.   
1. Expression of TLRs in hepatocytes 
A number of groups have investigated effects of TLR4, TLR9, TLR2, or 
TLR3 in the liver (256-260).  Yet the liver is also composed of stellate cells, 
Kupffer cells, epithelial cells and circulating and resident lymphocytes (261).  All 
of these cells express a number of innate immune receptors including TLRs (262).  
These cells also produce a significant amount of inflammatory cytokines via NF-
kB pathway and IFNs via IRF pathway (262).  Therefore, studies of TLRs in the 
liver do not reflect the expression or function of TLRs in individual cell types and 
since hepatocytes play host to HCV, we concentrated our work on purified 
hepatocytes.   
We determined the expression of TLR2, TLR1, TLR6 and TLR7 in human 
hepatoma cells and primary hepatocytes.  In doing so, we were able to postulate 
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that hepatoma cells are not only host to HCV but must be targeted for innate 
immune suppression in order for infection to continue or possibly occur.  
Hepatocytes compose around 80% of the liver and act in many ways to 
metabolize substances taken up in the body, either good or bad (263).  They 
produce bile to aid in the process of digestion, cholesterol and lipids for cellular 
membranes, break down and form carbohydrates in gluconeogenesis and store 
proteins; they also make clotting factors vital to the body’s initial defense 
mechanisms (263).  Of course classically, hepatocytes and the liver are most 
known for detoxifying the Friday night rendezvous so many of us make, a nice 
stiff drink of alcohol (264).  The liver is also the only known organ that can 
regenerate due to the restoring nature of hepatocytes (265).  It is quite an 
accomplishment that hepatocytes can also act in an innate immune function.  
Traditional to hepatocytes’ original occupation, we can conclude that in 
hepatocytes the expression of most TLRs, in particular TLR2, its co-receptors and 
TLR7, alert other immune cells of potentially harmful pathogens by inducing 
inflammatory cytokines.  R848, TLR7/TLR8 specific ligand has been shown to 
induce NF-κB activation after 7 hours in HEK293/TLR7 cells (266) and in murine 
peritoneal macrophages (267).  I did not see a measurable increase after one hour 
but to correctly ascertain NF-κB activation by R848 in hepatoma cells, I would 
perform a time course using R848 stimulation and obtaining nuclear extracts to 
run EMSAs using dsNF-κB oligonucleotides.  Another route would be to transfect 
in an NF-κB luciferase reporter construct into hepatoma cells and run a time 
course stimulating with R848.   
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A caveat to obtaining primary hepatocytes from outside sources is the lack 
of 100% purity of cell type.  Cambrex guarantees up to if not greater than 97% 
pure human primary hepatocytes.  There were no phenotyping tests for 
contaminating cells performed.  Three percent or fewer cells in the hepatocyte 
samples could be contaminating cells from the liver, such as Kupffer, stellate, or 
epithelial cells.  All of these cells can also contribute to not only the expression of 
TLRs but also the functional cytokine production upon stimulation with TLR 
specific ligands or HCV proteins.  We can not rule out the possibility that the 
TLR expression or the cytokine production could partially be from other cells.  
Even though the cells were allowed to recover from the stress of transportation, 
we can not also rule out the possibility that the cells were slightly activated and 
may express varying degrees of TLRs or innate immune genes from this 
activation.  There was no elevated baseline of cytokine production in the 
hepatocyte media during any of these experiments which assures us that any 
cellular stress or contamination was minimal if any and did not contribute to the 
activity of hepatocytes upon ligand stimulation.  
2. HCV proteins core and NS3 are responsible for increased 
inflammatory cytokine production in primary hepatocytes that have 
functional TLRs.   
Earlier we brought notice to the intriguing finding that TLR8, in 
particular, is fully expressed in mice yet dysfunctional (241).  A few have 
postulated whether the receptor is redundant in mice and therefore unnecessary.  
Studies with murine macrophages showed non-responsive TLR8 upon ligand, 
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R848, stimulation.  In humans both TLR7 and TLR8 are expressed and fully 
functional to R848, yet for reasons unknown TLR8 in mice may not be utilized.  
A possible caveat to this theory is the small yet disruptive difference in genomic 
sequences between mice and men (268), which could cause TLR receptors to 
malfunction when stimulated with functional ligands in mice possibly due to a 
point mutation that could cause misfolding of the receptor’s recognition site (269, 
270).  Because of this unanswered query, we sought to determine whether TLR 
expression in hepatocytes is functional or defunct.   
The lack of extracellular cytokine production in hepatoma cells forced us 
to investigate activation of TLRs via NF-kB translocation.  Only TLR2 and not 
TLR7 ligands were able to activate NF-kB in both hepatoma cell types, which we 
also saw with the little TLR2 mediated IL-6 and IL-8 production made from these 
cells (data not shown).  Stimulation with TLR2/1, TLR2/6 or TLR7 ligands in 
primary hepatocytes showed a rather large response of inflammatory cytokines 
and modest production of Type 1 IFNs.  Novel to these findings is the activation 
of purified primary human hepatocytes by HCV core and NS3.  HCV core and 
NS3 were shown to activate monocytes and murine macrophages in a TLR2 
specific manner.  We can thus postulate the likelihood that HCV core and NS3 
activation of hepatocytes is also a TLR2-mediated mechanism.    
Because the HCV proteins were recombinant fusion proteins with β-
galactosidase and produced in E. coli there is a chance that lipopeptides from E. 
coli were contaminating the HCV proteins.  The HCV proteins had only been 
purified by the company using affinity column purification stated in the methods.  
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We did not perform further purification steps but would consider in the future 
purifying the proteins further.  Since the limulus assay does not detect 
lipopeptides further purification using detergent extraction and isolation by 
reverse-phase high performance liquid chromatography may be necessary to 
assure purification of proteins.   
3. Consequences to hepatocyte activation 
IL-6 and IL-8 are important aspects of the immune response.  IL-6 acts as 
either a pro- or anti-inflammtory cytokine (271).  As an anti-inflammatory 
cytokine it can inhibit TNF-α, IL-1 and IL-10 (272).  As a pro-inflammatory 
cytokine it can cause a febrile response from release of prostaglandin E2 (273).  
Important to the acute phase response, IL-6 has also been implicated in 
modulation of osteoclast cells (274).  A consequence to chronic HCV is 
hepatocellular carcinoma (HCC) for which the mechanism for transformation of 
hepatocytes is not fully elucidated (275).  It could be possible that excess IL-6, 
which is required for Ras oncogenic behavior (276), from stimulated hepatocytes 
by the TLR2 or TLR7 receptors, contributes to the mechanism of HCC.  Even 
though these receptors proved functional, there was a preference for production of 
inflammatory cytokines, particularly IL-8, over Type 1 IFNs.  IL-8 is a 
chemokine that attracts and directs immune cells, such as: neutrophils, 
macrophages, mast cells (277).  There was a much larger IL-8 induction 
compared to IL-6 in hepatocytes which also occurred with HCV protein 
stimulation.  This huge influx of immune cells in acute infections could help 
cause spontaneous resolution of the infection, but in chronic infections a steady 
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influx of IL-8 or IL-6 production from HCV proteins or RNA eventually causes 
more damage than good.  We conclude that hepatocytes have a very important 
function in mediation of self created inflammatory cytokines, yet don’t seem to 
play as important of a role in Type 1 IFN generation.  Functional TLR2/1 or 
TLR2/6 receptors in hepatocytes provide further knowledge of the identity of 
cells producing inflammatory cytokines during HCV infection which in chronic 
infections leads to an over abundance of inflammatory cytokines causing damage 
to the liver.  Blocking TLR2 production of excess inflammatory cytokines during 
chronic HCV infection could be a novel therapy to aid in the fight against the 
virus.   
The lack of stimulation from TLR7 ligands in hepatoma cells could 
represent a mutation in the receptor due to carcinogenesis or possibly a 
methodology error.  Since primary hepatocytes administered with R848, resulted 
in a large IL-8 and moderate IL-6 production, the ligand performed as should.  
TLR7 is located within the endosome and therefore isolated from free flowing 
stimulants, whereas TLR2 exists both intracellularly but more importantly on the 
cell surface where upon the receptor is totally accessible to stimulants.  Primary 
hepatocytes were stimulated for ten hours or greater with R848, whereas 
hepatoma cells were stimulated for only 1 hour.  Due to the nature of the 
hepatoma cell lines and their inability to produce measurable amounts of 
extracellular cytokines upon stimulation, we could not test hepatoma cells using 
the ELISA technique.  On the other hand, it would be worth testing NF-κB 
activation in primary hepatocytes after one hour of stimulation to compare the 
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results with hepatoma cell lines.  Due to restrictions of obtaining enough primary 
hepatocytes for these experiments, NF-κB activation was not tested.  Extracellular 
cytokines were measured using ELISA after ten hour stimulation with R848 in 
primary hepatocytes whereas in hepatoma cells NF-κB was measured by EMSA.  
NF-κB activation occurs much faster than cellular production of cytokines and 
extracellular release, therefore samples for EMSAs were performed with a one 
hour ligand incubation compared to the ELISA testing where the cells were 
incubated with ligand for ten hours.  Activation of NF-kB occurs immediately in 
TLR2 receptors within 1 hour.  Since TLR7 is located within the endosome, 
ligands must fuse with TLR containing endosomes before ligands can bind and 
activate TLRs.  This process may take a longer time in accessing or allowing for 
endosomal maturation partially required by the receptor, thereby delaying NF-kB 
activation as opposed to TLRs located on the cell surface where ligands have 
immediate access to binding and activation of the receptor.  Although the NF-kB 
pathway was not activated after 1 hour, the TLR7/IRF7 pathway was activated 
upon R848 or R837 stimulation after 2 hours.  This phenomenon could be 
addressed by performing a time course with an NF-kB luciferase reporter assay 
transfected into hepatoma cells.   
On a molecular level, it is quite possible that TLR7 is engaged by HCV 
RNA.  TLR7 recognizes and is activated by single stranded RNA and polyU 
sequences.  HCV not only exists in a single stranded RNA form but also has a 
significant polyU sequence in the 3’NTR region.  Although there is strong 
evidence that TLR7 would recognize and become activated by HCV RNA, the 
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limitation to TLR7 recognition of HCV is based on its physical location strictly 
within the endosome.  HCV entry and fusion into the host cell results in release of 
its genomic material directly into the cytoplasm without contacting TLRs within 
the endosome (278).  Recent evidence suggests that HCV infection induces an 
incomplete autophagic response in hepatocytes (279).  Autophagy involves 
cellular membrane invagination around cytosolic products which the resulting 
autophagosome fuses with a lysosome leading to degradation.  TLR7 located 
within the endosome/lysosome recognizes vesicular stomatitis virus in this 
manner (226).  HCV replicating cells showed presence of autophagosomes and 
HCV infection led to an increase of autophagy despite different genotypes (279, 
280).  It is quite possible that HCV RNA is also recognized in this manner yet it is 
still unknown whether HCV RNA is present within these autophagosomes and 
whether they fuse efficiently with lysosomes containing TLR7.  The efficiency for 
autophagosomes to fuse with lysosomes and cause protein degradation was low in 
HCV replicating cells, and therefore without further evidence autophagy may not 
be the major recognition mechanism of HCV RNA by TLR7 (279).   
 
Both TLR2 co-receptors function in response to HCV core and NS3   
We established the identity and involvement of TLR2 and its co-receptors 
in cellular activation by HCV NS3 and core proteins in both human and mouse 
cells.  HCV core protein is found not only in the cell cytoplasm but is present 
circulating within the host blood stream.  Location of core outside of the virus and 
cell implicates the protein in immunogenicity.  HCV NS3 unlike core protein is 
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not located in the blood stream but has been shown to be immunogenic also with 
its ability to activate monocytes and dendritic cells (208, 281).  HCV does not 
induce cell lysis, but signaling to other immune cells from infected cells may 
cause their cell lysis.  Viral products such as HCV NS3 protein may be released in 
the serum upon cell death and it is here where it may be possible for NS3 to 
activate TLR2/1 or TLR2/6 on the cell surface.  We have also been able to locate 
TLR2 intracellularly by flow cytometry (data not shown).  NS3 protein as a 
protease cleaves TRIF and IPS-1 in the cytoplasm, therefore it is possible that 
NS3 may be autophagosized by the cell as a host cellular defense mechanism 
where TLR2/1 or TLR2/6 complexes may be traveling intracellularly to the 
surface.  These mechanisms might explain the activation induced from NS3 on 
TLR2 and its co-receptors.  Without further research in this area the exact 
mechanism is still unknown yet important to understand as NS3 is immunogenic. 
Here we show that HCV core and NS3 proteins activate not only 
monocytes (79), but also monocyte-derived macrophages to produce both TNF-α 
and IL-10.  We confirmed that TLR2 siRNA knockdown significantly reduced 
activation by HCV core and NS3 proteins.  Innate immune cells in the liver that 
are rich in TLRs include resident macrophages, Natural Killer (NK) cells, and 
Natural Killer T (NKT) cells, but also recruited monocytes and macrophages 
(282).  Since Kupffer cells, the resident hepatic macrophages, compose ~20% of 
the liver, we used macrophages derived from human monocytes to parallel 
Kupffer cells and to examine the effects of HCV core and NS3.  Kupffer cells 
produce the majority of TNF-α in the liver, which can mediate liver injury (167). 
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Here we show for the first time that TLR1 and TLR6 are involved in macrophage 
activation by HCV core and NS3 proteins.  Involvement of both TLR1 and TLR6 
receptors is another way for HCV infection to cause an inflammatory cytokine 
response.   
1. Both TLR1 and TLR6 are involved in TLR2 activation by HCV 
proteins 
Our results indicate that in human cells, the absence of either TLR1 or 
TLR6 had a dramatic negative effect on HCV core and NS3 stimulation, 
suggesting the involvement of both of these TLR2 co-receptors.  Selective 
silencing of only one co-receptor did not result in the complete loss of cytokine 
induction by the HCV ligands.  SiRNA knockdown of TLR1 or TLR6 showed 
very little cytokine production when stimulated with HCV proteins.  These results 
might suggest that HCV proteins utilize not only both TLR1 or TLR6 receptor, 
along with TLR2, but also that HCV proteins may require a complex of TLR2 and 
both heterodimers for full activation by the HCV proteins.  Knockdown of either 
TLR1 or TLR6 did not affect the others’ function as shown in Figure 4.4.  Due to 
an incomplete knockdown using RNAi technology, we utilized TLR2, TLR1, and 
TLR6 knockout mice.  In the knockout mouse model, our data demonstrate that 
HCV core and NS3 utilize the TLR2/TLR6 complex.  The observation of only 
minimal inhibition of HCV core or NS3 induced TNF-α in TLR1-/- suggests that 
in mice, recognition or activation by HCV core or NS3 proteins may not involve 
TLR1 as much as it may involve TLR6.  Since there was some downregulation of 
cytokine production in TLR1-/- mice upon HCV protein stimulation, it is possible 
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that TLR1 might contribute to slight recognition of HCV core and NS3.  Since 
HCV does not infect mice and their TLRs have slightly different sequences than 
humans, it is not surprising that there may be some differences in ligand 
activation between these two TLR2 co-receptors.  The mechanisms for HCV 
proteins to activate innate immune receptors in mice and in humans might also be 
different.  HCV does not infect mice; therefore the innate immune receptors in 
mice might not be as sensitive to HCV proteins.  HCV proteins which are 
accustomed to the human host may not have the conformation or sequence to 
stimulate mice receptors.   
2. Other receptors could be involved with TLR2 activation via HCV 
proteins 
We also found that, although there was a significant reduction in TNF-α in 
the HCV protein stimulated TLR6 knockout macrophages, residual cytokine 
production remained.  The residual cytokine could be due to a functional TLR2 
and an unknown co-receptor.  These results could imply alternate utilization of 
TLR1 or the possibility of another TLR2 co-receptor without the use of TLR1 or 
TLR6, such as CD36 (dectin-1) (201, 283) or CD14 (202).  It is unknown whether 
other possible co-receptors such as β3 integrins (284) or ganglioside GD1a (285) 
also utilize TLR1 or TLR6 when activating TLR2.  Alternatively, our results 
cannot rule out utilization of a different receptor in HCV core and NS3-induced 
innate cell activation.  Several groups demonstrated that HCV core protein can 
inactivate T cells via gC1qR (286-288) and the implication of gC1qR-mediated 
HCV-induced innate immune suppression awaits confirmation.  Recent reports 
135 
 
also indicate that HCV core protein may activate pro-inflammatory cell activation 
in an IFN-γ receptor-dependent manner (289, 290).  Others and we have 
previously reported that HCV core and NS3 proteins inhibits macrophage-derived 
dendritic cell differentiation and functional capacity (208, 291-293). 
3. Non-specificity of TLR2 and its co-receptors could lead to 
activation by many other viral products 
Utilization of either TLR1 or TLR6 as TLR2 co-receptors in macrophage 
activation by HCV core and NS3 proteins supports the potential for broad-range 
recognition and cell activation by these proteins.  Recent reports show that a 
number of viruses, such as cytomegalovirus (294, 295) and vaccinia virus (296), 
activate TLR2 and either TLR1 or TLR6 inflammatory cytokine response.  It is 
unclear as to whether specific TLR2, TLR1 and TLR6 receptor-mediated 
activation by HCV proteins is helpful or harmful to the host.  These proteins elicit 
both an inflammatory and anti-inflammatory response in human monocyte 
derived macrophages.  Considering that HCV core and NS3 proteins induce 
inflammatory cytokine production, TLR2-mediated signaling may represent a 
mechanism for non-specific inflammatory activation seen in chronic HCV.  In 
support of this contention, patients with chronic HCV infection exhibit an 
activated phenotype of Kupffer cells (297). However, it is not negligible that 
HCV core and NS3 proteins trigger production of IL-10, a potent anti-
inflammatory cytokine.  Such dual modulation of innate immunity by triggering 
both pro- and anti-inflammatory pathways seems to be common for TLR2-
signaling pathogens of different origin (298).  Further, in HCV infected patients 
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there are reports of elevated levels of serum IL-10 (299) and increased IL-10 
production in immune cells (300).  Importantly, the modulation of expression of 
TLR2 and its co-receptors in both immune and liver compartments is common for 
multiple liver diseases, including chronic HCV infection (38, 301). 
With recent research progress, the possibility of cytokine regulation and 
the modulation of TLR function for therapeutic purposes become realistic (196).  
Our data provide novel insight into the mechanisms of HCV protein-induced 
activation of immune cells and indicate a new potential direction in managing the 
imbalanced immune functions during chronic infection with Hepatitis C virus.  
 
TLR7: HCV’s newest target for immune evasion from IFNs 
 Immune evasion by HCV has been documented in a number of different host 
cell types and it has been suggested to play a key role in viral persistence and 
development of chronic infection (106, 178, 236, 302-304). HCV interferes with 
host defense at multiple levels: HCV NS3/4A cleaves the adaptor proteins TRIF 
and MAVS preventing further downstream signaling in the Type 1 IFN pathway 
(106, 178), core protein interferes with cell cycle progression and apoptosis (303), 
and NS5A binds MyD88, a central adaptor protein for TLR downstream signaling 
and inhibits anti-viral cellular activation (235).  NS5A could not fully inhibit IFN 
production by viral stimulation of TLRs in macrophages.  NS5A displayed a 
weaker inhibition using the TLR7 ligand R-837 than viral stimulation and 
therefore this HCV immune evasion mechanism can not fully explain the lack of 
TLR7 expression and decreased stability shown in chapter V.  It is possible that 
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NS5A may contribute to the small increase in IRF7 nuclear translocation of HCV 
replicating cells by inhibiting signaling through TLR7/MyD88.  Without further 
analysis I cannot conclude whether NS5A is involved in the stunted IRF7 nuclear 
translocation in HCV replicating cells.  Here we show that HCV employs a novel 
mechanism for immune evasion by specifically targeting TLR7 expression, 
mRNA stability, and function.   
1. Diminished TLR7 expression caused by HCV induced TLR7 RNA 
instability 
We identified a significant decrease of TLR7 expression in the presence of 
HCV infection both in vitro and in vivo.  We established the direct effect of HCV 
replication on TLR7 expression, as indicated by restoration of TLR7 levels upon 
viral suppression.  Among others, the most frequently encountered mechanisms of 
viral-dependent impaired expression of a cellular receptor include interference 
with gene transcription or protein translation, posttranscriptional and 
posttranslational receptor modifications and disruption of the downstream 
signaling events (249, 305, 306, 106). We identified that HCV infection, 
interferes at least with two of these events regarding TLR7. First, HCV infection 
interfered with the TLR7 gene during transcriptional regulation as shown by 
TLR7 mRNA instability in HCV replicating cells. Induction of host mRNA 
instability is a common evasion strategy employed by other viruses, including 
Herpesviruses, Vaccinia, and Influenza to bypass immune surveillance (249, 307, 
308). Among the mechanisms of induction of host mRNA instability are 
association of viral proteins with several members of the mammalian exosome, 
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activation of the exosomal enzymes and/or recruitment of the exosome to 
mRNAs, usage of the exosome as a vehicle to access cellular mRNAs if the viral 
protein possesses RNase activity and enhancement of exosomal activity whether 
or not viral functions as an RNase; most often viruses employ more than one 
mechanism to achieve total or partial host shutoff (309, 310).  
2. Further HCV-induced mechanisms for reduced TLR7 expression 
The detailed mechanisms of HCV-induced TLR7 mRNA instability are 
yet to be discovered; it is unknown whether HCV produces siRNA’s targeting 
TLR7 mRNA, exploits host regulatory factors that bind to TLR7 mRNA or uses 
an HCV protein to aid the TLR7 mRNA instability.  HCV requires the use of liver 
specific host microRNA, miR122, for HCV replication (311).  Further studies 
confirmed the utilization of RNAi by HCV for efficient viral replication (312).  
During HCV viral replication, it is quite possible that a product from viral RNA 
cleavage could target TLR7 mRNA in the cytoplasm.  Although there is no 
evidence yet that HCV produces an siRNA to target TLR7, there is evidence that 
other viruses in plants have the ability to target host mRNA for degradation by 
producing their own viral siRNAs (313).  Nevertheless, impaired TLR7 mRNA 
stability results in low levels of TLR7 protein expression during HCV infection.  
Since we did not investigate the mechanisms for reduced TLR7 protein, it may be 
possible that HCV utilizes the ubiquitin machinery to target TLR7 protein for 
degradation, thus reducing protein expression.   
It is not impossible to ponder that HCV-induced TLR7 mRNA instability 
is not solely responsible for the observed impaired TLR7 protein levels. Several 
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viruses affect different steps of the host protein expression, including 
transcriptional, posttranscriptional and posttranslational modifications; such 
possibility in regards to TLR7 remains to be analyzed in the case of HCV (314, 
315). Finally, by analogy with TLR3 and RIG-I/MDA-5, HCV may partially 
interfere with TLR7-mediated signaling pathways. We identified impaired TLR7-
mediated activation of IRF7 in HCV replicating cells compared to controls. 
Because the baseline activation in HCV replicating cells was higher compared to 
controls, we concluded that TLR7-independent activation of IRF7 signaling 
pathways was intact in the presence of HCV infection. Baseline IRF7 activation 
has been correlated with endogenous IFN levels in some cells while other ligands 
like LPS have been shown to activate IRF7 also.  In addition to TLR7, a number 
of other receptors can activate IRF7, such as TLR8, TLR9 or TLR3.  It is 
unknown whether these receptors may play a role in the basal activation of both 
control hepatoma and HCV replicating cells.  Further, these data narrowed TLR7 
as a specific target of HCV by the fact that only TLR7, but not TLR5 was targeted 
during HCV infection suggesting the specific influence.  
3. IFN-induced exhaustion from HCV infection? 
A decrease in TLR7 levels during HCV infection might not affect the 
production of Type 1 IFNs via TLR7 signaling; therefore we tested whether the 
Type 1 IFN pathway was functional in the remaining TLR7 receptors.  Our results 
revealed the TLR7-induced IRF7 nuclear translocation was significantly increased 
in control cells but it failed to appreciably enhance further from elevated 
background activation of IRF7 in HCV infected cell lines.  These results indicated 
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that the remaining TLR7 receptors cannot fully compensate in function for the 
diminished TLR7 levels.  We can not rule out the possibility that the high IRF7 
baseline in HCV infected cells could cause an immune exhaustion of Type 1 IFN 
production.  Further IFN production by viral stimulation could inhibit activation 
of other anti-viral interferon stimulated genes creating a negative feedback loop 
(316, 317).  Suppressors of cytokine signaling (SOCS) expression is induced by 
Type 1 IFNs and SOCS are known to inhibit the IFNα receptor pathway (318).   
Recent reports suggested a substantial cellular activation in HCV 
replicating cells and HCV infected patients without external stimuli (196, 247, 
254, and 319).  In chronically infected HCV patients, several groups reported an 
increase of interferon-stimulated genes (ISGs) before therapy and regardless of 
stimulation (247, 319).  These reports support our findings of the initially high 
IRF7 nuclear translocation in the absence of stimulation in HCV replicating cells 
and suggest pre-activation of IRF7 nuclear translocation due to HCV infection.  
In conclusion, we identified that HCV interferes with TLR7 expression 
and function. Our findings aid the understanding of the HCV-induced immune 
evasion mechanisms. 
Model of Mechanisms 
 We propose a representative model for TLR2 co-receptor activation by HCV 
proteins in Figure 6.1.  I propose that TLR1 and TLR6 in conjunction with TLR2 
are activated by HCV proteins which stimulate the receptors to activate a cascade 
of events that produces a large quantity of inflammatory cytokines.  These 
inflammatory cytokines can activate other adjacent cells in the liver, cause cell 
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death by over stimulation, immune cell deactivation by negative regulators 
stimulated by inflammatory cytokines.  All of these effects of TLR1, TLR6, and 
TLR2 activation by HCV proteins may participate in creating a more permissive 
environment for HCV infection persistence.  This research has left the possibility 
of other TLR2 co-receptors that are activated by HCV proteins or other receptors 
beyond TLR2 that are activated by HCV proteins. 
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Figure 6.1: TLR2 co-receptor mechanism model for cellular activation by HCV core and NS3 
proteins.  HCV proteins representated by the black star and blue moon binds TLR2/1 or TLR2/6 
complexes with the possibility of TLR2/? receptor that also is activated by HCV proteins.  TLR2/1 
or TLR2/6 activation leads to initiation of events dependent on the MyD88 pathway that results in 
translocation of numerous transcription factors, in particular NF-κB, into the nucleus.  
Inflammatory cytokines produced by these events can cause cell activation, cell death, or immune 
cell deactivation which can all aid in chronic HCV infection. 
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HCV does not induce cell lysis, but signaling to other immune cells from 
infected cells may cause their cell lysis.  Viral products such as HCV NS3 protein 
may be released in the serum upon cell death and it is here where it may be 
possible for NS3 to activate TLR2/1 or TLR2/6 on the cell surface.  We have also 
been able to locate TLR2 intracellularly by flow cytometry (data not shown).  
NS3 protein as a protease cleaves TRIF and IPS-1 in the cytoplasm, therefore it is 
possible that NS3 may be autophagosized by the cell as a host cellular defense 
mechanism where TLR2/1 or TLR2/6 complexes may be traveling intracellularly 
to the surface.  These mechanisms might explain the activation induced from NS3 
on TLR2 and its co-receptors.  Without further research in this area the exact 
mechanism is still unknown yet important to understand as NS3 is immunogenic. 
Immune evasion mechanisms are highly prevalent in chronic HCV 
infected cells.  In Figure 6.2, I outline the mechanism of HCV immune evasion 
involving reduced TLR7 levels and decreased mRNA stability.  HCV infection 
correlates with reduced TLR7 mRNA and protein levels in hepatoma cells.  HCV 
replication causes decreased TLR7 mRNA stability but increased endogenous 
IRF7 nuclear translocation.  Reducing TLR7 RNA expression will ultimately 
reduce TLR7 protein expression as there is less RNA to translate from.  Lowered 
TLR7 levels will reduce the Type 1 IFN response and inflammatory cytokine 
response.  We did not investigate the mechanism of how TLR7 mRNA expression 
is destabilized or possibly reduced.  HCV core has been found in the host nucleus 
and it is possible that core may bind to sites, such as IRF1, within the region of 
the TLR7 promoter to negatively regulate TLR7 transcription.  Increased 
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endogenous IRF7 levels may cause cytokine tolerance or exhaustion as an 
overabundance of cytokines can cause activation of negative regulators that 
inhibit anti-viral pathways or also TLR7 transcription pathways.  It is unclear 
whether the stunted IRF7 nuclear translocation response from TLR7 ligand 
stimulation is due to the already increased endogenous IRF7 translocation levels 
or the decreased TLR7 levels.  We did not explore the possibility that HCV 
infection may inhibit TLR7 protein stability as a mechanism for the reduced 
TLR7 protein levels.  By decreasing TLR7 expression and yet another Type 1 IFN 
inducible pathway, hepatocytes are more permissive for chronic HCV infection. 
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Figure 6.2: Model for contributions to HCV persistence: reduction of TLR7 expression.  
Model of possible mechanisms to reduced TLR7 expression in HCV replicating hepatoma 
cells.  HCV RNA shown as a red curved line goes through replication in the cytoplasm and 
within the endoplasmic reticulum (ER) membrane.  This replication causes reduced TLR7 
mRNA (shown in purple) stability which ultimately reduces TLR7 protein expression.  HCV 
infection also causes increased IRF7 translocation shown with the red and green arrow, yet 
upon TLR7 activation, there was a stunted increase of IRF7 nuclear translocation.  A 
mechanism for reduced TLR7 expression could be HCV protein negative regulation in the 
nucleus by inhibiting binding sites at the TLR7 promoter.  Another possible mechanism to 
reduced TLR7 expression could be inhibition of the protein by increasing TLR7 protein 
degradation.  All of these mechanisms could contribute to chronic HCV infection. 
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Conclusions 
 The results presented in this composition show various mechanisms for the 
manipulation of the host innate immune system by Hepatitis C virus.  We provide 
evidence for two separate means that the virus upon infection utilizes for survival 
in the liver.  One mechanism involves an immune exhaustion by Kupffer cells and 
hepatocytes in which HCV stimulates these cells to manufacture excessive 
amounts of inflammatory cytokines, IL-8, IL-6, and TNF-α.  This mechanism has 
the possibility to not only confuse the adaptive immune system by over 
stimulating the cells and masking infection but also to exhaust both arms, innate 
and adaptive, of the immune system ultimately leading to tolerance or anergy.  
Treatment for infection will not clear the virus unless the host has working 
defense mechanisms.  The other mechanism is quite the opposite of stimulating 
the cells non-specifically, but quietly manipulating anti-viral facets of the cell to 
leave it unprotected.  HCV immune evasion is well documented among the innate 
faction, from HCV NS3/4A cleavage of TRIF and MAVS to HCV E2 or NS5A 
binding and inhibition of PKR.  Increased degradation of TLR7 RNA is a 
completely novel mechanism exhibited by HCV, yet well used among other 
viruses.  Despite their opposing natures, when exploited together, HCV as an ever 
developing virus against host immunity is able to assemble these mechanisms for 
near invincible survival.   
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